University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

2-14-2017

Compounds Including Cox Inhibitor Moiety and Enhanced Delivery
of Active Drugs Using Same
Audra Stinchcomb
Kyung Bo Kim
University of Kentucky, kyung.kim@uky.edu

Ragotham Reddy Pinninti
University of Kentucky, rrpinn2@email.uky.edu

Priyanka Ghosh
Kalpana S. Paudel

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Stinchcomb, Audra; Kim, Kyung Bo; Pinninti, Ragotham Reddy; Ghosh, Priyanka; and Paudel, Kalpana S.,
"Compounds Including Cox Inhibitor Moiety and Enhanced Delivery of Active Drugs Using Same" (2017).
Pharmaceutical Sciences Faculty Patents. 168.
https://uknowledge.uky.edu/ps_patents/168

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been
accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

Illlll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
US009566341B 1

c12)

United States Patent

(10)

Stinchcomb et al.

(45)

(54)

COMPOUNDS INCLUDING COX INHIBITOR
MOIETY AND ENHANCED DELIVERY OF
ACTIVE DRUGS USING SAME

(75)

Inventors: Audra Stinchcomb, Baltimore, MD
(US); Kyung Bo Kim, Lexington, KY
(US); Ragotham Reddy Pinninti,
Lexington, KY (US); Priyanka Ghosh,
Baltimore, MD (US); Kalpana S.
Paudel, Knoxville, TN (US)

(73)

Assignee: University of Kentucky Research
Foundation, Lexington, KY (US)

( *)

Notice:

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 711 days.
This patent is subject to a terminal disclaimer.

(21)

Appl. No.: 13/458,366

(22)

Filed:

Apr. 27, 2012

Related U.S. Application Data

(60)

Provisional application No. 61/517,874, filed on Apr.
27, 2011.

(51)

Int. Cl.
A61K 47148
(2006.01)
(2006.01)
A61K 9170
(2006.01)
A61K 9100
U.S. Cl.
CPC ........... A61K 471481 (2013.01); A61K 910021
(2013.01); A61K 917023 (2013.01)
Field of Classification Search
None
See application file for complete search history.

(52)

(58)

(56)

References Cited

U.S. PATENT DOCUMENTS
6,569,449
7,229,556
7,232,460
7,511,054
7,759,358
2002/0094515
2002/0098472
200210111377
2002/0111551
2003/0032892
200410180036

Bl
Bl
B2
B2
B2
Al
Al
Al
Al
Al
Al *

2005/0154002
2005/0266061
2008/0008745
2008/0076789
200910017102
2009/0036523
2009/0143762
2009/0156814
2009/0246265
2009/0247619

Al
Al
Al
Al
Al
Al
Al
Al
Al
Al

5/2003
6/2007
6/2007
3/2009
7/2010
712002
712002
8/2002
8/2002
212003
912004
7/2005
12/2005
1/2008
3/2008
1/2009
212009
612009
612009
10/2009
10/2009

Stinchcomb et al.
Hinds, III et al.
Van Erlach et al.
Stinchcomb et al.
Crooks et al.
Erlach et al.
Erlach et al.
Stinchcomb
Erlach et al.
Erlach et al.
Ashton
Crooks et al.
Stinchcomb et
Stinchcomb et
Stinchcomb et
Stinchcomb et
Stinchcomb et
Stinchcomb et
Stinchcomb et
Stinchcomb et
Stinchcomb et

al.
al.
al.
al.
al.
al.
al.
al.
al.

Patent No.:
US 9,566,341 Bl
Date of Patent:
*Feb.14,2017

2009/0291128
2010/0273895
2011/0052694
2011/0245288
2011/0245783
2012/0034293

Al
Al
Al
Al
Al
Al

11/2009
10/2010
3/2011
10/2011
10/2011
2/2012

Stinchcomb
Stinchcomb
Stinchcomb
Stinchcomb
Stinchcomb
Stinchcomb

et
et
et
et
et
et

al.
al.
al.
al.
al.
al.

OTHER PUBLICATIONS
Definition of "compound" and "composition" from the Grant &
Hackh's Chemical Dictionary (1987) p. 148, McGraw-Hill, Inc.*
Miranda, H.F., Prieto, J.C., Pinardi, G. (2005) Spinal synergy
between nonselective cyclooxygenase inhibitors and morphine
antinociception in mice. Brain Research, vol. 1049, p. 165-170.*
Dhooper, Harpreet Kaur, "Opioid-Cannabinoid Codrugs With
Enhanced Analgesic and Pharmacokinetic Profile" (2010). University of Kentucky Doctoral Dissertations. Paper 98. <http://
uknowledge.uky.edu/gradschool_diss/98>.*
Hermanson, G.T. (1996) "Zero-Length Cross-linkers" in
Bioconjugate Techniques, p. 617-618, Academic Press, Elsevier.*
Zalipsky, S. (1995) Functionalized Poly( ethylene glycol) for Preparation of Biologically Relevant Conjugates. Bioconjugate Chemistry, vol. 6, p. 150-165.*
Ghosh, P. et al "Optimization of natrexone diclofenac codrugs .
"Pharm. Res. (2014) vol. 31, pp. 148-159.*
King, A. et al "Effects of naltrexone on smoking cessation ... " J.
Clin. Pharmacol. (2012) vol. 32, pp. 630-636.*
Reece AS (2011) Hypothalamic opioid-melanocortin appetitive
balance and addictive craving. Med Hypotheses 76 (1):132-137.
Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y and Patra J (2009) Global burden of disease and injury
and economic cost attributable to alcohol use and alcoholuse
disorders. Lancet 373 (9682):2223-2233.
Roberts WJ and Sloan KB (1999) Correlation of aqueous and lipid
solubilities with flux for prodrugs of 5-fluorouracil, theophylline,
and 6-mercaptopurine: A Potts-Guy approach. J Pharm Sci
88(5):515-522.
Roche DJ, Childs E, Epstein AM and King AC (2010) Acute HPA
axis response to naltrexone differs in female vs. male smokers.
Psychoneuroendocrinology 35(4):596-606.
Rukstalis MR, Stromberg MF, O'Brien CP and Volpicelli JR (2000)
6-beta-naltrexol reduces alcohol consumption in rats. Alcohol Clin
Exp Res 24(10):1593-1596.
Schuckit M (2009) Alcohol-use disorders. Lancet 373:492-501.
Shaw D and al' Absi M (2010) Blunted opiate modulation of
prolactin response in smoking men and women. Pharmacol
Biochem Behav 95(1):1-5.
Sinha R (2007) The role of stress in addiction relapse. Curr
Psychiatry Rep 9(5):388-395.
Soyka Mand Rosner S (2010) Emerging drugs to treat alcoholism.
Expert Opin Emerg Drugs 15(4):695-711.
Stinchcomb AL, Dua R, Paliwal A, Woodard RW and Flynn GL
(1995) A solubility and related physicochemical property comparison ofbuprenorphine and its 3-alkyl esters. Pharm Res 12( 10): 15261529.

(Continued)
Primary Examiner - Leigh C Maier
(74) Attorney, Agent, or Firm - Stites & Harbison
PLLC; Mandy Wilson Decker
A61K 31/196
424/85.l

(57)
ABSTRACT
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COMPOUNDS INCLUDING COX INHIBITOR
MOIETY AND ENHANCED DELIVERY OF
ACTIVE DRUGS USING SAME

2003, the number of prescriptions for two buprenorphine
formulations for the treatment of opioid dependence
increased from 48,000 ($5 million) to 1.9 million ($327
million) in 2007 (Mark, 2009). Unfortunately, the buprenorphine sublingual tablets have a very bitter taste and potential
for "peak" plasma drug level related side effects (dizziness,
sedation, orthostatic hypotension), and the poor acceptance
of the drug has limited the use.
Alcohol use disorders (AUDs) are a major public health
problem (Breese et al., 2005; Koob and Le Moal, 2005;
Sinha, 2007), and alcohol abuse is one of the leading causes
of death in the United States, contributing to over 80,000
deaths annually (Mokdad et al., 2004). Alcohol consumption
accounts for 9% of the disease burden in developed countries and is linked to more than 60 diseases including
cancers, cardiovascular diseases, liver cirrhosis, neuropsychiatric disorders, injuries and fetal alcohol syndrome (Casswell and Thamarangsi, 2009; Schuckit, 2009; WHO, 2004).
Prescriptions for alcoholism increased from 393,000 ($30
million) in 2003 to 720,000 ($78 million) in 2007. Disulfiram, naltrexone, and acamprosate prescriptions dominate
the market (Mark, 2009).
The leading cause of preventable deaths in the United
States is cigarette smoking, with over 440,000 premature
deaths occurring each year. Cigarette smoking is known to
reduce appetite and increase the rate of cellular metabolism,
leading to body mass stabilization or reduction. One of the
main reasons for recidivism in persons trying to quit smoking is the potential for weight gain, especially in women.
Regardless of the varied findings of the many studies on
smoking cessation and weight gain, the primary recommendation has been to incorporate weight loss treatment with
smoking cessation. Naltrexone (NTX) may be a potential
weight loss drug candidate, especially in combination with
bupropion (Greenway et al., 2009; Greenway et al., 2010;
Ioannides-Demos et al., 2011); and the biochemical relationship between appetite and addictive craving is receiving
increasing attention (Reece, 2011). Interesting positive clinical results have been seen when women smokers are treated
with a combination ofNTX and nicotine patches (Epperson
et al., 2010; Roche et al., 2010; Shaw and al'Absi, 2010).
Good clinical trial results and preclinical data have shown
a reduction in amphetamine and methamphetamine use with
NTX treatment (Grant et al., 2010; Haggkvist et al., 2009a;
Haggkvist et al., 2009b; Karila et al., 2010). Studies with
many other drugs have shown a lack of success for methamphetamine dependence treatment, therefore NTX may be
a very good option (Karila et al., 2010).
Naltrexone (NTX), an opioid antagonist, is currently
prescribed as an oral tablet or 30-day depot injection form to
help maintain opioid addicts in a drug-free state. Unfortunately, postmarketing reports of serious injection site reactions (cellulitis, abscess, and necrosis) have recently
required patient warning updates for the depot injection, and
the oral dosage form is associated with many gastrointestinal
side effects. NTX is also FDA-approved for the treatment of
alcohol dependence. Substantial clinical evidence exists for
the benefits of NTX treatment in smoking cessation, especially in women. Very intriguing clinical trial data has also
been observed in amphetamine-dependent individuals,
which is especially important as methamphetamine dependence has no FDA-approved treatment options. Preclinical
data also exists that suggests that NTX may benefit anabolic
androgenic steroid dependency. Treatment with NTX in the
90's produced variable success rates in addicts; however,
current clinical NTX therapy is being optimized based on
human pharmacogenetic data.

RELATED APPLICATIONS
This application claims priority from U.S. Provisional
Application Ser. No. 61/517,874 filed Apr. 27, 2011, the
entire disclosure of which is incorporated herein by this
reference.
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GOVERNMENT INTEREST
This invention was made with govermnent support under
NIH R01DA13425 awarded by the National Institutes of
Health. The govermnent has certain rights in the invention.
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TECHNICAL FIELD
The presently-disclosed subject matter relates to compounds including a cyclooxygenase enzyme inhibitor moiety. In some embodiments, the compound includes a Cox
inhibitor moiety and an opioid. The compounds allow for
improved microneedle-enhanced delivery rates across skin,
as well as an increase in the pore lifetime or duration of
delivery.

20

25

INTRODUCTION
According to the National Survey of Drug Use and Health
(NSDUH) of 2008, 7 .2 million Americans are in need of
treatment for Substance-Related Disorders (SRDs), and a
large proportion of those need treatment for opiate pain
reliever and heroin addiction. Additionally, over 8.5% of the
U.S. population and 75 million people worldwide meet the
diagnostic criteria for alcohol use disorders (AUDs), with
alcohol abuse being among the top three preventable public
health problems in the U.S. and the world.
Opioid and alcohol abuse are major worldwide problems
connected with tremendous social and personal strife. The
CDC reported in February 2011 that the abuse of and deaths
from prescription opioid narcotics has reached epidemic
levels. In May 2009 the Columbia University National
Center on Addiction and Substance Abuse reported that
$468 billion dollars were spent by the Govermnent in 2005
on expenses related to smoking, alcohol abuse, and illegal
drugs. Prevention, treatment and addiction research spending comprised only about 2% of that $468 billion. Taxpayers
would benefit if more of that budget were spent on treatment
options, rather than law enforcement expenses and the
healthcare cost burden that comes from patients who
develop cirrhosis, lung and cardiovascular disease, and a
variety of cancers, not to mention the expense of emergency
room visits for overdoses.
The latest NHSDA (National Household Survey on Drug
Abuse) report conducted by the Substance Abuse and Mental Health Services Administration reported in July 2007 that
nearly one in 12 full time workers in the US have serious
enough drug/alcohol problems to require medical treatment.
The 2008 National Survey of Drug Use and Health (NSDUH) estimated that approximately 7.2 million Americans
were in need of treatment for illicit drug use. Unfortunately,
most of these individuals do not seek treatment. However,
for those who do seek treatment, the third and fourth most
common substance abuse types are opiate pain reliever and
heroin, respectively. Providing recovery help for addicts
with pharmacological interventions has proven helpful. In

30

35

40

45

50

55

60

65

US 9,566,341 Bl
3

4

Transdermal delivery of NTX is desirable for addicts in
order to help reduce side effects associated with oral (hepatotoxicity at high doses in hepatocompromised addicts) and
injectable therapies, and improve compliance. Permeation
through the skin allows the drug to directly enter the
systemic circulation and avoid the first pass effect. NTX
itself does not have the essential physicochemical properties
that would allow a therapeutic dose of the drug to cross the
human skin barrier.
Microneedle (MN)-enhanced transdermal delivery is an
efficient and painless method for increasing the skin permeation of many drugs, including NTX. The major limitation
of MN-enhanced delivery is that the micropore lifetime only
allows delivery of drug for two to three days. Therapeutic
viability ofNTX treatment would be improved by a product
that allows for less-frequent treatment.
Accordingly, there remains a need in the art for novel
compounds and methods that allow for a therapeutically
successful drug delivery system that allows for less-frequent
administration.

Compounds of the presently-disclosed subject matter are
useful for use in a therapeutically-successful delivery system
that allows for less-frequent dosing. In some embodiments,
the compounds can be used in an MN transdermal delivery
system to provide a therapeutic transdermal delivery rate of
an opioid antagonist (e.g., naltrexone or naltrexol). Contemplated delivery rates across the skin are improved because of
optimized physicochemical properties for faster diffusion.
In some embodiments, the opioid from which the first
moiety is derived is selected from: naltrexone, buprenorphine, butorphanol, codeine, cyclazocine, cyclorphan,
oxilorphan, dihydrocodeine; dihydromorphine, ethymorphine, hydromorphone, levallorphan, levorphanol, nalbuphine, nalmefene, nalorphine, naloxone, naltrexol, phenazocine, and pholcodine. In some embodiments, the opioid
antagonist is naltrexsone or naltrexol.
In some embodiments, the COX enzyme inhibitor from
which the second moiety is derived is selected from:
diclofenac,
SC560, valeryl
salicylate, mofezolac,
FR122047, celecoxib, ibuprofen, and ketoprofen. In some
embodiments, the COX enzyme inhibitor is diclofenac.
In some embodiments, the opioid from which the first
moiety is derived is selected from: naltrexone, buprenorphine, butorphanol, codeine, cyclazocine, cyclorphan,
oxilorphan, dihydrocodeine, dihydromorphine, ethymorphine, hydromorphone, levallorphan, levorphanol, nalbuphine, nalmefene, nalorphine, naloxone, naltrexol, phenazocine, and pholcodine; and the COX enzyme inhibitor from
which the second moiety is derived is selected from:
diclofenac,
SC560, valeryl
salicylate, mofezolac,
FR122047, celecoxib, ibuprofen, and ketoprofen.
In some embodiments, the opioid antagonist is naltrexone
or naltrexol and the COX enzyme inhibitor is diclofenac.
In some embodiments, the compound includes a linker
moiety. In some embodiments, the opioid antagonist and the
COX enzyme inhibitor are linked by a linker moiety. In
some embodiments, the linker moiety is cleavable. In some
embodiments, the linker moiety is cleavable by hydrolysis
and/or enzymatic digestion. In some embodiments, the
linker moiety inparts improved aqueous solubility to the
compound.
In some embodiments, the compound comprises a structure selected from a structure as set forth in FIG. 2.
The presently-disclosed subject matter further includes a
method for treating a subject, including identifying a subject
in need of treatment for a condition selected from the group
consisting of pain, depression, narcotic dependence, alcohol
dependence, amphetamine dependence, smoking dependence, and anabolic-androgenic steroid dependence; and
delivering to the subject a therapeutically effective amount
of a compound of the presently-disclosed subject matter.
In some embodiments, a method for treating a subject
includes identifying a subject in need of treatment for a
condition selected from the group consisting of pain, depression, narcotic dependence, alcohol dependence, amphetamine dependence, smoking dependence, and anabolic-androgenic steroid dependence; and delivering to the subject a
therapeutically effective amount of a compound of the
presently-disclosed subject matter, wherein following delivery to the subject, the compound is transformed into at least
two active drug molecules. In some embodiments, the
transformation is by hydrolysis and/or enzymatic digestion.
The compound can be delivered in a variety of manners. In
some embodiments, the compound is delivered transdermally.
In some embodiments, the compound can be transdermally delivered by microneedle, wherein the compound
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SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This Summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
Cyclooxygenase (COX) enzyme inhibitors, such as
diclofenac, can prolong the lifetime of micropores of
microneedle (MN)-enhanced transdermal delivery systems,
allowing delivery of a drug to extend beyond a few days,
allowing for less-frequent patch dosing (e.g., once a week).
Many of the COX inhibitors are weak acids, and opioid
antagonists, such as naltrexone and naltrexol, and many
other desirable transdermal drugs are weak bases. It is
difficult to formulate high concentrations of a weak base and
a weak acid in the same system, due to chemical stability and
solubility issues.
The presently-disclosed subject matter includes compounds including a first moiety derived from an drug of
interest; and a second moiety derived from a cyclooxygenase (COX) enzyme inhibitor, wherein the first moiety is
linked to the second moiety to form a single chemical entity.
The compounds of the presently-disclosed subject matter
improved microneedle-enhanced delivery rates across skin,
as well as an increase in the pore lifetime or duration of
delivery. Without wishing to be bound by theory or mechanism, the cox inhibitor component of the compound allows
for pores to remain open for a longer time period, allowing
for improved delivery of the first moiety/drug of interest. In
some embodiments, the first moiety is derived from a drug
with a phenolic hydroxyl or hydroxyl group. In some
embodiment, the first moiety is derived from an opioid. In
some embodiments, the first moiety is derived from an
opioid antagonist.
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achieves improved duration of microporation-assisted delivery of the drug of interest (from which the first moiety of the
compound is derived), as compared to the parent drug of
interest (as administered independent from the compound
including first and second moieties as described herein). In
some embodiments, the improvement of duration of
microporation-assisted delivery of the drug of interest (e.g.,
from a single patch) is an improvement of greater than 1, 2,
3, 4, 5, 6, or 7 days.

microneedles that had pores that closed up did not show this
type of staining, so the effect means the pores are viable.
This technique has been used by others to visualize micropores in other studies. Pores heal quickly after the patches are
removed (Banks et al., 2010).
FIG. 10 is a graph showing how plasma concentration
changes with a change in flux rate.
FIG. 11 Solubility profile of naltrexone and diclofenac
generated using predicted chemical property values from
Scifinder®.
FIG. 12 Structure of parent drugs, (a) naltrexone, (b)
diclofenac (c) 3-0-ester codrug and (d) hydrochloride salt
form of 3-0-ester codrug.
FIG. 13 Stability study profile for codrug in hairless
guinea pig plasma indicating pseudo first order kinetics.
(n=3).
FIG. 14 In vitro diffusion study across full thickness
Yucatan miniature pig skin of the base form of the compound of FIG. 2U (A) Steady state flux of naltrexone and
diclofenac from the codrug at 48 hours post MN treatment.
(n=3) (B) Skin concentration over time from the base form
of the compound of FIG. 2U. Both naltrexone and
diclofenac concentration could be observed in the skin
indicating the regeneration of the parent molecules. n=3 for
12 h, 24 hand n=2 for 36 hand 48 h.
FIG. 15 In vitro diffusion study across full thickness
Yucatan miniature pig skin comparing the base form on the
codrug to the hydrochloride salt form. The steady state flux
values of naltrexone are reported from codrug base (n=3)
and codrug salt (n=4).
FIG. 16 includes a graph showing flux ofnaltrexone from
different formulations of the compound of FIG. 2U. In vitro
diffusion study across full thickness Yucatan miniature pig
skin comparing the flux of naltrexone at steady state from
different donor formulations. Propylene glycol (PG) was
used in different concentrations to optimize formulation for
in vivo studies (n;;,;3)
FIG. 17 is a series of pictures of visualized hairless guinea
pig micropores (A) immediately following MN treatment,
(B) at day 4 following treatment with MN followed by
application of NTX HCl gel under occlusion, and (C)
visualized by India ink staining wherein the HCl salt form of
the compound was used following MN treatment indicating
that the pores can stay open up to a 7 day time point.
FIG. 18 is a graph showing flux of NTXol in a study
involving the compound of FIG. 2V.
FIG. 19 In vitro diffusion study across full thickness
Yucatan miniature pig skin comparing the flux of naltrexone
at steady state from naltrexone HCl, salt form of the codrug
and previously studied formulation for in vivo human pharmacokinetic studies (n>3).
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph showing solubility of naltrexone and
diclofenac as a function of pH; pH 5 is the ideal value for
topical formulation.
FIGS. 2A-2W are structures of exemplary embodiments
of compounds of the presently-disclosed subject matter,
where n is 1, 2, 3, or 4 in FIGS. 2C-2J, 2M, and 2N, and n
is 4, 5, or 6 in FIGS. 2K and 2L.
FIG. 3 describes the specific decision making for compounds of the presently-disclosed subject matter, as
described in the present Examples.
FIG. 4 is a graph showing NTX flux comparison from a
human study with MN and NTX patches (Wermeling et al.,
2008), the compound of FIG. 2A (codrug) salt, and an
optimized NTX HCl formulation with 10% propylene glycol
(PG). The human study used 60% PG, which causes a
decrease in flux due to the viscosity increase (Milewski and
Stinchcomb, 2011). The optimized NTX HCl flux is a target
for embodiments of the compound.
FIG. 5 is a graph showing skin concentrations of
diclofenac after treatment with Solaraze gel in Yucatan
miniature pig skin in vitro with MN treatment and non-MN
treated controls. Daily application of Solaraze was applied
to the skin to mimic the in vivo hairless guinea pig study
where microneedle treated pores stayed open for 7 days
(FIG. 7).
FIG. 6 includes graphs showing skin concentrations in
Yucatan miniature pig skin in vitro after MN treatment and
application of the compound of FIG. 2A (codrug). Experiments were terminated and skin disposition measured at 12,
24, 36, and 48 h. Flux values correlated with the skin
disposition data, as the flux of NTX from the codrug was
twice as high as the diclofenac flux, further proving the
higher retention of diclofenac in the skin. The flux of NTX
was also measured over 48 h from the compound of FIG. 2A
and its HCl salt.
FIG. 7 is a graph showing NTX plasma levels in hairless
guinea pigs after application of NTX gel alone or NTX gel
and Solaraze (diclofenac gel). A control containing the
hyaluronic acid in Solaraze was also tested, and an extension
in micropore lifetime was not observed. No significant
depletion from the NTX control gel was identified, as only
a few percent of the total drug was delivered (Banks et al.,
2011).
FIG. 8 is a graph showing NTX plasma concentrations in
Yucatan miniature pig (n=3 trials) after topical dosing for 72
h with an NTX hydrogel and a single MN application. Time
points from 72 to 96 hours are after patch removal. No NTX
was detected when the same formulation (& patch area)
applied to the pig without MN treatment. Similar to human
results, showing the need for micropore closure inhibition.
Intravenous NTX was evaluated in the pigs in order to
determine the clearance of NTX and NTXOL.
FIG. 9 is a picture of hairless guinea pig micropores
visualized with India ink at the end of the 7 day experiment
with the compound of FIG. 2A (codrug). Skin treated with
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The presently-disclosed subject matter includes compounds including a first moiety derived from a drug of
interest; and a second moiety derived from a cyclooxygenase (COX) enzyme inhibitor, wherein the first moiety is
linked to the second moiety to form a single chemical entity.
Compounds of the presently-disclosed subject matter are
sometimes referred to herein as codrugs. A codrug comprises two different drugs within a single chemical entity.
The two drugs may be connected either directly or by means
of a cleavable, biolabile covalent linker. Many diseases are
treated by a combination of therapeutic agents that are
co-administered in separate dosage forms. However; there
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are potential advantages in delivering the co-administered
agents as a single chemical entity. One advantage is that
often, when the two drugs are chemically linked together in
the codrug structure, the resulting physicochemical and
pharmacokinetic properties of the codrug are superior to
those of the individual parent drugs.
The term "derived from" indicates that the first and
second moieties of the compounds have a structure of a
parent drug of interest and COX inhibitor that have been
modified as is necessary to be connected to the remainder of
the compound, while maintaining some or all of the activity
associated with the parent compound, or while obtaining
enhanced activity relative to the parent compound. For
example, a moiety derived from a drug of interest and COX
inhibitor can have the structure of the drug of interest and
COX inhibitor, less a leaving group (e.g., less a hydrogen,
less a hydroxyl, less a covalent bond, or less another leaving
group) or including a connecting group, as will be apparent
to one of ordinary skill in the art.
The compounds of the presently-disclosed subject matter
provide for improved microneedle-enhanced delivery rates
across skin, as well as an increase in the pore lifetime or
duration of delivery. Without wishing to be bound by theory
or mechanism, the cox inhibitor component of the compound allows for pores to remain open for a longer time
period, allowing for improved delivery of the first moiety/
drug of interest. In some embodiments, the first moiety is
derived from a drug with a phenolic hydroxyl or hydroxyl
group. In some embodiment, the first moiety is derived from
an opioid. In some embodiments, the first moiety is derived
from an opioid antagonist.
Exemplary first moieties of the compounds of the presently-disclosed subject matter can be derived from opioids
including, but not limited to naltrexone, buprenorphine,
butorphanol, codeine, cyclazocine, cyclorphan, oxilorphan,
dihydrocodeine, dihydromorphine, ethymorphine, hydromorphone, levallorphan, levorphanol, nalbuphine, nalmefene, nalorphine, naloxone, naltrexol (including 6-beta naltrexol and 6-alpha naltrexol), phenazocine, and pholcodine,
and other opioids known to those skilled in the art.
Exemplary second moieties of the compounds of the
presently-disclosed subject matter can be derived from COX
enzyme inhibitors including, but not limited to diclofenac,
SC560, valeryl salicylate, mofezolac, FR122047, celecoxib,
ibuprofen, ketoprofen, and other COX inhibitors known to
those skilled in the art, including non-steroidal anti-inflammatory drugs (NSAIDs), COX-1 inhibitors and COX-1specific inhibitors, and COX-2 inhibitors and COX-2-specific inhibitors.
In some embodiments of the compound, the opioid
antagonist is naltrexone or naltrexol, and the COX enzyme
inhibitor is selected from diclofenac, SC560, valeryl salicylate, mofezolac, FR122047, celecoxib, ibuprofen, and ketoprofen. In some embodiments of the compound, the opioid
antagonist is naltrexone or naltrexol, and the COX enzyme
inhibitor is diclofenac. In some embodiments of the compound, the opioid antagonist is naltrexol and the COX
enzyme inhibitor is diclofenac.
In some embodiments, the compound has more than one
first moiety derived from an opioid antagonist and/or more
than one second moiety derived from a COX inhibitor,
wherein each of the first moieties and each of the second
moieties are independently selected (e.g., each of the more
than one first moieties need not be derived from the same
opioid antagonist and/or each of the more than one second
moieties need not be derived from the same COX inhibitor.

In some embodiments, the opioid antagonist and the COX
enzyme inhibitor are joined by a linker moiety or more than
one linker moiety. The linker moiety(ies) can be a cleavable
linker moiety(ies) such as ester, thioester, carbonate, carbamate, thiocarbamate, amide, thioamide, ureide, or any
other suitable chemical moieties, providing that the chemistry is feasible. It will be recognized by the skilled artisan
that desirable linker moieties can be bioconvertible or biolabile. In some embodiments the linker moiety(ies) is cleavable via hydrolysis or enzymatic digestion.
Exemplary compounds of the presently-disclosed subject
matter are set forth in FIGS. 2A-2W.
The presently disclosed subject matter also includes methods of treating a subject for conditions including pain,
depression, and substance dependence, including narcotic
dependence, alcohol dependence, amphetamine dependence, smoking dependence, and anabolic-androgenic steroid dependence. As used herein, dependence is inclusive of
addiction and is inclusive of any disorder associated with
dependence and/or addiction; as such, alcohol dependence,
for example, is inclusive of alcohol abuse and alcoholism.
In some embodiments, a method of the presently-disclosed subject matter includes identifying a subject in need
of treatment for a condition selected from the group consisting of pain, depression, narcotic dependence, alcohol
dependence, amphetamine dependence, smoking dependence, and anabolic-androgenic steroid dependence; and
delivering to the subject a therapeutically effective amount
of a compound of the presently-disclosed subject matter.
Without wishing to be bound by mechanism, following
delivery to the subject, the compound is transformed into at
least two active drug molecules.
Subjects who can benefit from the methods of the present
invention include, for example, mammals, such as humans,
particularly humans who are suffering from pain, depression, and/or substance dependence.
"Treatment" or "treating," as used herein, refers to complete elimination as well as to any clinically or quantitatively
measurable reduction in condition for which the subject is
being treated. The methods of the presently-disclosed subject matter include delivering a therapeutically effective
amount of the compound. A "therapeutically effective
amount," as used herein, refers to an amount, determined by
one skilled in the art, sufficient for treating the condition for
which the subject is being treated.
The compound can be delivered to a subject transdermally, intravenously, orally, buccally, sublingually, by topical creams, subdermally, as a sustained release depot, ophthalmically, intranasally, aurally, by inhalation, rectally or
vaginally.
In some embodiments, transdermal delivery is used. In an
exemplary method for transdermal delivery of the compound, the steps comprise contacting a section of skin with
the compound and biotransforming the compound into two
drugs by skin enzymes or by hydrolysis of the compound in
the skin. A transdermal patch comprising a suitable substrate
and a layer of the compound can be employed to deliver the
compound to the skin.
The compound can be administered as a pharmaceutical
composition comprising pharmaceutically acceptable carriers, diluents, and/or excipients, which are vehicles commonly used to formulate pharmaceutical compositions for
animal or human administration. The carriers, diluents and/
or excipients are not intended to have biological activity
themselves, and are selected so as not to affect the biological
activity of the compound and any other active agent(s). A
pharmaceutically acceptable carrier, diluent, and/or excipi-
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ent as used herein includes both one and more than one such
carrier, diluent, and/or excipient. Examples include but are
not limited to distilled water, saline, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution,
and Hank's solution. Depending upon the manner of introduction, the compound can be formulated as, for example, a
sterile injectable formulation comprising aqueous solutions
and/or suspensions containing the active materials in admixture with suitable carriers, diluents, and/or excipients.
The concentration of compound, the formulation (i.e., a
formulation that is therapeutically effective to the subject to
which it is administered) and the dose administered can be
readily determined by a person of ordinary skill in the art.
Typically, dosages used in vitro and in animal models, such
as in the experiments provided in the present application,
can provide useful guidance in the amounts useful for in
vivo administration.
The compound can be applied to the skin as a topical
cream, salve, ointment, gel, or other topical formulation;
and/or by using delivery devices such as bandages, occlusive bodies, patches, and/or the like. The area of skin to
which the compound is applied can optionally be pre-treated
with microneedles or other microporation devices, as are
known to those of ordinary skill in the art.
Illustratively, a composition of the compound that is
applied to the skin can be formulated as a topical cream,
salve, gel, or ointment. The topical formulations can include
inert diluents and carriers as well as other conventional
excipients, such as wetting agents, preservatives, and suspending and dispersing agents. In addition to the above,
generally non-active components, topical formulations containing compound can further include other active materials,
particularly, active materials which have been identified as
useful in the treatment of the condition for which the subject
is being treated, for example substance addiction, and which
can usefully be delivered transdermally to the subject. For
instance, such other active materials can include acamprosate, disulfiram, topiramate, sertraline, rivastigmine, citalopram, and doxepin. The topical formulation can be applied
directly to the skin and then optionally covered (e.g., with a
bandage of gauze) to minimize the likelihood of its being
disturbed. Alternatively, the topical formulation can be
coated on the surface of a bandage, gauze, etc., and the
bandage, gauze, etc. can then be applied to the skin of the
subject such that the topical formulation is in direct contact
with the subject's skin.
Alternatively, the compound can be delivered transdermally to the subject by formulating compound into a bandage, pad, or other type of patch which can be applied to the
subject's skin.
Illustratively, matrix-type transdermal patches, in which
the compound is disposed in an adhesive matrix, can be
employed. The matrix-type transdermal patch can further
include other active materials for transdermal delivery to the
subject with the compound. Suitable adhesives for use in
such matrix-type transdermal patches include polyisobutylenes, acrylates, silicone, hydrogels, and combinations
thereof. Still other patches suitable for use in the practice of
the present invention are known to those of ordinary skill in
the art.
In another illustrative embodiment, the bandage, pad, or
other type of patch can be one which is capable of controlling the release of the compound such that transdermal
delivery of the compound to the subject is substantially
uniform and sustained over a period of at least 12 hours,
such as at least 24 hours, at least 48 hours, at least 3 days,
at least 4 days, at least 5 days, at least 6 days, and/or at least

7 days. Such a bandage, pad, or other type of patch which
can be used in the practice of the method of the present
invention can take the form of an occlusive body. In practice,
the occlusive body which includes the compound is positioned on the subject's skin under conditions effective to
transdermally deliver the compound to the subject's skin.
In some embodiments, the methods of the presentlydisclosed subject matter can make use oftransdermal delivery using microneedles. The microneedle strategy suitable
for use in the presently-disclosed subject matter is not
particularly limited, but includes any microneedle strategy
that can be employed to facilitate the transdermal delivery of
compounds described herein.
As used herein, the term "microneedles" refers to a
plurality of elongated structures that are sufficiently long to
penetrate through the stratum corneum skin layer and into
the epidermal/dermal layer, yet are also sufficiently short to
not activate nerve endings and cause pain.
Various microneedles that can be employed to facilitate
transdermal delivery of compounds of the presently-disclosed subject matter are described in printed publications
and are known to those of ordinary skill in the art. Suitable
microneedles have been fabricated from many materials,
including silicon, metals, and polymers.
The microneedles can be solid or hollow. If solid
microneedles are used, channels can be made by poking the
skin with a microneedle array, followed by removal of the
needles and then application of the drug. Alternatively, the
solid microneedles can be inserted and left in the skin,
allowing diffusion through the gaps between the
microneedles and the surrounding tissue. Solid microneedles
can also be coated with the compound prior to insertion into
the skin. Alternatively, microneedles containing a hollow
bore can be used to transport drugs through the interior of
the needles by diffusion or pressure-driven flow. Hollow
microneedles can act as mini hypodermic injection needles.
In some embodiments, the microneedles can be used to
create a microneedle-treated site prior to applying the compound to the microneedle-treated site. As noted above, the
microneedles can be inserted and left in the skin. In some
embodiments, a microneedle array comprised of solid
microneedles can be used to increase skin permeability by
inserting the microneedles into the skin and then removing
the microneedles to create a microneedle-treated site prior to
applying the compound to the microneedle-treated site.
Optionally, the microneedles can be repeatedly inserted and
removed, at the same site. Typical microneedle arrays comprise 15-200 microneedles, but can include any number of
microneedles that is desired.
The microneedles can be inserted and removed to create
a microneedle-treated site on the subject's skin under conditions effective to transdermally deliver the compound
upon application of the compound. Such conditions can
include, for example, positioning the microneedle-treated
site on a portion of the subject's skin which is not covered
with hair, and/or shaving the hair from the selected portion
of the subject's skin.
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
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understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, ifthe value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include prophetic descriptions,
and/or compilations of data and information that are representative of data and information gathered at various times
during the course of development and experimentation
related to the present invention.

and development for improved pharmacologic treatments
for drug and alcohol abuse are very important. Naltrexone
(NTX), an opioid antagonist, is currently prescribed in oral
tablet and injectable form to help maintain opioid addicts in
a drug free state. Most recently, naltrexone has been indicated as an adjunct in the treatment of alcohol dependence,
as well as reported to reduce alcohol craving in certain
alcoholic populations. Unfortunately, postmarketing reports
of serious injection site reactions (cellulitis, abscess, and
necrosis) have recently required patient warning updates for
the 30-day NTX depot injection. Additionally, high oral
doses that may be needed for therapeutic effect in addicts
can cause hepatotoxicity. Substantial clinical evidence exists
for the benefits of NTX treatment in smoking cessation,
especially in women (Epperson et al., 2010; Roche et al.,
2010; Shaw and al'Absi, 2010; Toll et al., 2010). Very
intriguing clinical trial data has also been observed in
amphetamine dependent individuals, which is especially
important as methamphetamine dependence has no FDAapproved treatment options (Grant et al., 2010; Haggkvist et
al., 2009a; Haggkvist et al., 2009b; Karila et al., 2010).
Preclinical data also exists that suggests that NTX may
benefit anabolic-androgenic steroid dependent people (Kanayama et al., 2010a; Kanayama et al., 2010b). Treatment
with NTX in the 90's and early 2000's produced variable
success rates in addicts; however, current clinical NTX
therapy is being optimized based on human pharmacogenetic data (Barr et al., 2010; Fortin et al., 2010; Ray et al.,
2010a; Ray et al., 2010b). Transdermal delivery ofnaltrexone is desirable for addicts and alcoholics in order to help
reduce side effects associated with oral (bypass first-pass
effect) and injectable therapy and improve compliance.
Naltrexone itself does not have the essential physicochemical properties that would allow a therapeutic dose of the drug
to cross the human skin barrier. Microneedle-enhanced
transdermal delivery is an efficient and painless method for
increasing the skin permeation of many drugs, including
naltrexone (Prausnitz, 2004; Wermeling et al., 2008). The
major limitation of microneedle-enhanced delivery is that
the micropore lifetime only allows delivery of drug for two
to three days (Banks et al., 2010; Milewski et al., 2010;
Wermeling et al., 2008).
Diclofenac and other relevant cyclooxygenase (COX)
enzyme inhibitors can prolong the lifetime of the micropores
to seven days, allowing for once a week patch dosing, the
transdermal delivery ideal goal (Banks et al., 2011 ). Many of
the COX inhibitors are weak acids, and naltrexone and many
other desirable transdermal drugs are weak bases. It is
difficult to formulate high concentrations of a weak base and
a weak acid in the same system, due to chemical stability and
solubility issues. The present inventors disclose herein compositions (sometimes referred to herein as codrugs), which
are covalently linked yet biolabile combinations of an opioid
antagonist (e.g., naltrexone) and a COX inhibitor (e.g.,
diclofenac ), in order to make a therapeutically successful
once a week drug delivery system. It is contemplated that
codrugs of naltrexone in combination with microneedle
treatment will provide a 7-day therapeutic transdermal delivery rate of naltrexone, and that these codrugs will make
excellent research tools for investigating quantitative structure permeability relationships (QSPR) for transdermal flux
and optimization of flux and micropore lifetime in combination with microneedle enhancement. These codrugs/microneedles should improve naltrexone delivery rates across
the skin because of optimized physicochemical properties
for faster diffusion.

EXAMPLES
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Example 1
An objective of the exemplary studies described herein
include improvement of drug therapy for opioid, smoking,
methamphetamine, alcohol and other relevant addiction
recovery by creating transdermal dosage form with longer
intervals between dosing, e.g., at least 7-day (once-a-week
dosing).
Alcoholism and drug addiction lead to major healthrelated problems and societal costs for people in the United
States and the rest of the world as well. Therefore, research
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A series compounds (FIG. 2) were designed to elucidate
fundamental QSPRs for microneedle-enhanced transdermal
flux optimization and subsequent bioconversion rates. Characterization of the physicochemical properties of the codrugs, including molecular volume, lipophilicity, hydrogenbonding potentials, melting points, heats of fusion,
hydrolysis kinetics, and solubilities in select solvents is
contemplated. The present inventors also contemplate measuring the drugs' penetration, concurrent bioconversion, and
COX inhibitor deposition in skin in vitro with microneedle
use. Also contemplated is characterization of the pharmacokinetics of the compounds in animals (e.g., guinea pigs
and Yucatan miniature pigs in vivo, and humans) with
microneedle use. Correlation of the in vitro data with the in
vivo model will aid in the creation of a reliable QSPR
database that is useful to determine relative efficacy of
compounds for clinical use. The studies will incorporate a
parallel pharmacodynamic (micropore closure) and drug
delivery/pharmacokinetic approach to identify novel codrug
treatments for significant clinical problems, such as opiate,
smoking, methamphetamine and alcohol addiction.
As noted herein naltrexone (NTX) is an opioid antagonist
that is currently used to help maintain opioid addicts in a
drug-free state. Most recently, naltrexone has been indicated
for use in treatment of other substance dependencies, e.g.,
alcohol dependence, including use to reduce alcohol craving
in certain alcoholic populations (Garbutt, 201 O; Gueorguieva et al., 2010; Martinotti et al., 2010; Morley et al.,
2010; O'Malley, 1996; O'Malley et al., 1992; Soyka and
Rosner, 2010; Volpicelli et al., 1992; Zarkin et al., 2010).
Pharmacogenetic analysis has been shown to improve NTX
treatment outcomes in clinical trials for alcoholism (Barr et
al., 2010; Fortin et al., 2010; Kranzler and Edenberg, 2010;
Kranzler et al., 2000; Ray et al., 2010a; Ray et al., 2010b).
NTX Hydrochloride is currently commercially available in
the United States as a 50-mg oral tablet (ReVia®), as well
as in generic form. Naltrexone undergoes extensive firstpass metabolism and has oral bioavailability estimates ranging from five to forty percent (PDR). Naltrexone is also a
hepatotoxin that has the capacity to cause dose-related
hepatocellular injury. This hepatotoxicity limits dosage
increases in those addicts who may benefit from more than
a 50-100 mg per day oral dose. Transdermal delivery would
circumvent these liver-related problems by allowing lower
doses to be used, because first-pass metabolism is bypassed.
Certainly, the ability to decrease the drug dosage would
benefit the already hepato-compromised alcoholic or narcotic addict. Many of the adverse effects seen with ReVia®
oral therapy (abdominal pain, constipation, nausea, and
vomiting) could also be reduced by transdermal therapy.
Compliance, the major problem with addict recovery pharmacological intervention, is likely improved when side
effects are reduced and drug doses are adequate to reduce
craving (O'Malley, 1996; O'Malley et al., 1992). One goal
of this research is to enhance the therapeutic value of
naltrexone by reducing side effects and improving addict
compliance with transdermal delivery that allows for dosing
of at least about 7 days. Several once-a-week transdermal
patches are on the market and are very popular.
The major problems with addict naltrexone use are motivation and compliance, which have prompted the development of 30-day depot dosage forms (Garbutt et al., 2005;
Kranzler et al., 2000). The depot dosage form (Vivitrol,
approved by the FDA in the summer of 2006) has been
shown to be effective in clinical trials with opiate addicts and
alcoholics, which bodes well for the patch, as the plasma
drug concentration profiles would be similar after depot

injection or patch treatment. In contrast to depot dosage
forms, transdermal systems offer a patient freedom from
injections (a 380 mg NTX as 1.1 g microsphere intramuscular injection), surgical implantations, and the healthcare
costs associated with implant dosing. Injection site reactions
are one of the most common Vivitrol adverse events.
Another advantage of transdermal dosing is the ability to
terminate the drug dose input at any time by simply removing the patch. The process of terminating drug input from the
depot injection requires surgical removal of microspheres
from the muscle, which might be necessary if a patient
requires opiate treatment for pain in an emergency situation
that occurs within the 30-day window where plasma levels
of naltrexone are released. A transdermal patch provides
sustained-release of a drug for a maximum of about one
week. Once-a-week dosing is certainly more desirable than
the three to seven times a week dosing of the currently
available ReVia®. The transdermal patch delivery system
suits the addict population well, being similar to the patchwearing population of nicotine addicts. A transdermal system that delivered a therapeutic dose of naltrexone into the
body for one week would certainly be consistent with a
weekly visit to an addict recovery clinic or probation officer.
As compliance is the major concern in nonmotivated criminal addicts, use of an adhesive that sticks to the skin only
once could be a helpful clue for a probation officer looking
for the noncompliant addict. This could deter an addict from
removing his/her patch during the week, knowing that
punishment for showing up with a non-stick patch would be
likely.
A very promising use of a transdermal NTX system is as
an adjunct in the treatment of alcohol dependence. Transdermal delivery of the potential hepatotoxin naltrexone will
bypass first-pass liver metabolism and also decrease gastrointestinal side effects. A relatively motivated alcoholic
would certainly want the ease of use and reduction of side
effects possible with transdermal delivery. In fact, compliance has been a critical issue in the response of alcoholics to
naltrexone therapy in recent clinical trials (Volpicelli et al.,
1997). Alcohol use has been shown to decrease by about
one-half in adult alcoholics taking naltrexone (Pettinati et
al., 2010; Volpicelli et al., 1997). Additionally, there is one
case report of an adolescent male that describes 30-day
abstinence during naltrexone alcohol-dependence treatment.
The prevalence rate of adolescent alcohol dependence
appears to be about four to ten percent, according to some
self-reported epidemiological studies. Thus, transdermal
delivery of naltrexone may also prove useful in the adolescent alcohol-dependent population, as well as in adults.
Naltrexone itself does not have the essential physicochemical properties that would allow a therapeutic dose of
the drug to cross the human skin barrier. Prodrugs contain
covalently bound chemical moieties added to a drug to make
it more permeable, but these prodrugs are rapidly bioconverted back to the active parent compound after dosing or
absorption. A codrug contains two active drug molecules
covalently linked together to improve the delivery or other
properties of one or both drugs (Kiptoo et al., 2006; Kiptoo
et al., 2008; Strasinger et al., 2008). In this case, the acid
functionality is being removed (temporarily masked) from
one of the drugs by forming a codrug so that the weak acid
COX inhibitor and the weak base NTX can be combined at
high concentrations in one dosage form without stability or
solubility incompatibility issues (FIG. 1). The naltrexone
delivery rate will be enhanced with codrugs designed to
optimize microneedle-assisted delivery for NTX flux as well
as micropore lifetime.
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Verification of codrug NTX delivery enhancement with an
applicable in vitro/in vivo transdermal delivery correlation
will help identify the most promising codrug for eventual
human use. This validation of in vitro/in vivo correlation
will be especially important in microneedle-assisted delivery, where optimal and efficient testing methods are just
being developed for this new and rapidly growing area of
drug delivery. Increased understanding of the quantitative
structure-permeability relationships (QSPRs) for transdermal codrug flux and concurrent bioconversion in vivo will
be attained by statistically comparing calculated codrug
physicochemical parameters, experimentally-derived physicochemical parameters, and diffusion study data. This way
the data gathered here can be applied to the design of other
transdermal codrugs for use with microneedle-assisted
delivery.
Skin Permeation: The skin consists of two major layers,
the outer epidermis and the inner dermis. The stratum
corneum, the outermost 10-15 µm of the epidermis, is
responsible for the skin's excellent diffusional resistance to
the transdermal delivery of drugs. Most of the skin's enzymatic activity lies in the basal cell layer of the viable
epidermis. Many researchers (Potts et al., 1997; Potts and
Guy, 1992; Roberts and Sloan, 1999) have developed skin
permeability relationships based on the physicochemical
parameters (molecular weight, molecular volume, lipophilicity, hydrogen-bonding potentials, polarity, etc.) of skin
penetrants. In the proposed project, these useful permeability models will be correlated with transdermal codrug diffusion, while taking into account complications of concurrent bioconversion of the codrug.
Transdermal Prodrugs and Codrugs (Mutual Prodrugs):
Studies performed by R. J. Scheuplein et al. in the 1960's
spurred pharmaceutical scientists to make use of new information concerning passive permeability and metabolism
properties of the skin. Since transport is a highly restricting
factor to successful topical use of drugs and since it is the
physical properties of a drug that largely determine the upper
limit to transport, attention was soon focused on manipulating the physical properties of drugs to improve delivery.
Models for evaluating transdermal prodrug delivery began
to appear in the pharmaceutical literature in the late 1970's
(Yu et al., 1979). Over the last thirty years some other
scientists have described possible transdermal prodrug
delivery for drugs such as fluorouracil, naproxen, acyclovir,
indomethacin, morphine, estradiol, and theophylline. A few
people have written comprehensive reviews about transdermal prodrug delivery, but this usually appears as a minor
subject in broadly based articles on prodrugs.
One transdermal delivery review incorporated codrugs
and prodrugs (Strasinger et al., 2008). Prodrugs specifically
to be used with microneedle-enhanced transdermal delivery
are also not readily available in the literature yet (Milewski
et al., 201 Oa; Milewski et al., 201 Ob). After three decades of
transdermal prodrug/codrug delivery study, the field still
seems relatively young with relatively small amounts of
literature published in the area, and no products on the
market. Synthesizing specific codrugs with varying physicochemical properties and systematically studying how the
transport and bioconversion of these codrugs are affected by
these physicochemical properties will give us a greater
database of transdermal codrug knowledge. Publication of
the results of these carefully controlled in vitro and in vivo
diffusion experiments with corresponding statistical relationships to physicochemical codrug properties (QSPR) will
greatly add to the prodrug/codrug literature. The ability to
choose the design of a successful prodrug/codrug based on

simple calculated and experimentally measured parameters
could save the pharmaceutical chemist valuable time and
effort.
With skillful formulation and addition of skin penetration
enhancers, some borderline delivery candidates can be made
into transdermally useful therapeutic agents. Penetration
enhancers are chemicals that alter the structure of the
stratum corneum temporarily in order to open up a pathway
for faster diffusion of drugs through skin. A major disadvantage to penetration enhancer use in transdermal delivery
systems is the potential for skin irritation and allergic
reaction. Skin irritation is a very common reason why many
topical and transdermal dosage forms do not make it to the
market. A major advantage of using transdermal prodrugs/
codrugs with prompt bio-activation is that their skin irritation and allergenic potential should only mirror the profile of
the parent drug(s), without the possible added toxicities of
penetration enhancers.
Successful delivery of NTX has been shown in humans
using microneedle enhancement for two to three days (Wermeling et al., 2008). Use of microneedles with optimized
codrugs will enable naltrexone delivery rates to increase
multiple-fold over passive delivery patches, without irritating enhancers, and with the added advantage of improving
the delivery duration from one patch to 7 days, the optimal
transdermal dosing goal.
Therapeutic Goal: From the standpoint of making NTX
transdermally useful, the present inventors contemplated a
need for a temporary form of NTX with optimized properties to substantially increase its flux (from 3 nmol/cm2 /hr to
about 12-90 nmol/cm 2 /hr). The most recent depot injection
clinical trial for alcohol dependence indicates that the
required flux would be 34-68 nmol/cm2 /hr from a 20 cm 2
patch (Garbutt et al., 2005). If the patch size is doubled, the
required flux rate would be reduced by one half. With
microneedle treatment alone, the present inventors found
that NTX could be delivered at the lower end of the
therapeutic range for opiate receptor blockade in humans, 2
ng/mL (Verebey et al., 1976).
The main therapeutic goal is to achieve a substantial
increase in the flux of the codrug across the skin to reach
effective levels in the body. This codrug would also supply
an equimolar dose exposure to diclofenac (or other future
COX inhibitors of choice). The minimum daily effective
systemic therapeutic dose of diclofenac is 75 mgx0.55 oral
bioavailability (Micromedex 1.0), or 41 mg per day. This
translates to a required systemic delivery rate of 270 nmol/
cm2 /hr from a 20 cm2 patch, which is several-fold higher
than the required systemic NTX flux.
Therefore, since the required NTX flux is the target for
systemic therapy, the diclofenac absorbed would be subtherapeutic because its use in the codrug is only to deposit
into the skin and maintain the pore lifetime through a
localized effect. As diclofenac is a potent COX inhibitor,
many other COX inhibitors could be used that would have
a local effect and very little systemic effect.
6-~-Naltrexol (NTXOL) is the major metabolite formed
by rapid reduction ofNTX in humans (Cone et al., 1974) and
in several other animal species, including guinea pigs
(Valiveti et al. 2004). NTXOL may contribute to the therapeutic action ofNTX in drug and alcohol dependence due to
its significant plasma concentrations (Ferrari et al., 1998;
Meyer et al., 1984; Wall et al., 1981) and longer terminal
half life (McCaul et al., 2000a; McCaul et al., 2000b;
Rukstalis et al., 2000; Wall et al., 1981) in humans compared
to NTX. The NTXOL half-life ranged from 7.5 to 13 hours
compared to 2-10 hours for NTX in these human subjects.
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Additionally, NTXOL exerted a 4-9 times longer duration of
action than NTX in different animal model experiments
involving rats and mice. NTXOL is also an opioid antagonist
with a similar affinity for the opioid receptors but with a
lower potency than NTX in in vivo studies. However, the
lower potency can be expected to be compensated by the
presence of a much higher plasma concentration, suggesting
that NTXOL might contribute a major role in the efficacy of
NTX.
Recent studies have provided evidence that NTXOL may
be of future relevance with respect to treatment of alcoholics
as well. A preclinical study by Stromberg et al. showed that
when given alone, NTXOL reduced alcohol consumption in
rats in a dose-dependent manner. This was also confirmed in
a second study (McCaul et al., 2000a; McCaul et al., 2000b ).
In addition, serum concentrations of NTXOL have been
shown to be associated with reductions in number of drinks
per month (O'Malley et al., 1992) and with potentially
important negative subjective effects of alcohol in humans
(McCaul et al., 2000a; McCaul et al., 2000b ). In a randomized, double-blind clinical trial of NTX, subjects with a
NTXOL level of more than 40 ng/ml did not experience an
alcohol relapse (O'Malley et al. 1992), indicating that the
relapse rate might be lower in patients treated with NTXOL.
In addition, since NTXOL is mainly excreted through the
renal route, it would be a safer alternative than NTX in
hepato-compromised patients. All this indicates that
NTXOL would be a useful therapy in drug addiction and
alcoholism. Thus, the present inventors contemplate analogues of NTXOL for transdermal delivery, and consideration of the present inventors' codrug designs with NTXOL,
to see if significant flux enhancement for this promising drug
can be achieved (Paudel et al., 2005).
Microneedle Enhancement: Microneedle delivery is in its
infancy stages of development for transdermal drug delivery, but the microelectromechanical systems (MEMS) class
that microneedles stemmed from is a multibillion dollar
market (McAllister et al., 2003). While microneedle insertion for transdermal drug delivery is new, it has shown
promising results that show increased drug permeation; it is
also a relatively painless drug delivery procedure (Kaushik
et al., 2001). There are currently many other devices on the
market, such as the ImplaJect™, Luer-Jet™, Iject® and
Mini-Ject™, to deliver therapeutics systemically by needlefree injection. The overriding problems associated with
these models are that they are costly to produce, require
medical supervision for application, and importantly are not
pain-free (Furness).
The microneedle would, on the other hand, cost much less
to produce and purchase, require no office visit for application, and would be pain-free. Initial studies with
microneedles have shown significant increases in the permeation oflarge molecules such as insulin (McAllister et al.,
2003). The design of the microneedle is based on the
composition of skin, because it must pass through the
stratum corneum (10-15 µm) and into viable epidermis or
dermal layers. In theory, the microneedle must only be long
enough to pass through the first 15 µm of skin, but most
microneedles are significantly longer. It is pertinent that a
microneedle works to produce a significant aqueous channel
through the epidermis so that continual drug delivery
through this channel can occur before reversal (channel
closing) is observed.
Examples of microneedle systems include BioValve's
Micro-Trans™ microneedle array patch and 3M's Microstructured Transdermal
Systems
(MTS).
Several
microneedle systems are in late-stage clinical trials. No

codrugs have been proposed for use in connection with
microneedle systems heretofore. In order to obtain the
fastest drug delivery rates possible, optimization of codrug
solubility, hydrogen bonding, and bioconversion rates will
need to be completed.
In order to increase understanding of the QSPRs for
transdermal codrug flux and concurrent bioconversion, one
should start with the basics. The original 3-alkyl-ester,
carbonate, and carbamate prodrug series for passive transdermal permeation served as the first building block in the
design of better prodrugs (Pillai et al., 2004; Stinchcomb et
al., 2002; Vaddi et al., 2009; Vaddi et al., 2005). This newly
proposed microneedle-enhancement project provides a validated methodology of studying the effects of a simple and
relatively stable skin esterase enzyme system on di-conjugation of the NTX molecule, to determine if significant
enhancement is achieved over and above the enhancement
seen with the mono-conjugated codrugs of NTX. The precise balance among lipophilicity, hydrophilicity, and metabolic bioconversion needs to be found for these codrugs, in
order to maximize NTX flux rates across the skin and
optimize COX inhibitor deposition into the skin simultaneously. Different polar and/or hydrophilic codrugs with varying properties will be especially suitable for the microneedle
flux optimization (Banks et al., 2010; Banks et al., 2008), as
diverse prodrug forms are known to significantly change
absorption rates of injectable drugs, if one considers
microneedle delivery to be a micro-injection.
There are currently no transdermal prodrug, codrug (mutual prodrug), or microneedle products on the market. The
present inventors contemplate the following innovative features in connection with embodiments of the presentlydisclosed subject matter.
Microneedles--carefully controlled models for transdermal delivery candidate selection, formulation, and
micropore lifetime optimization will be evaluated using the
"poke and patch" technique for systemic drug delivery. Most
prior research in microneedle-assisted transdermal delivery
has been for vaccines, biodegradable microneedles or coatings for very potent drugs, or in optimization of needle
engineering. Currently, the present inventors' human
microneedle NTX pharmacokinetic study is the only published report in this area using the "poke and patch" technique (Prausnitz and Langer, 2008; Wermeling et al., 2008).
There is also an ongoing clinical trial for microneedleassisted delivery of parathyroid hormone and a human proof
of concept study for insulin delivery using hollow
microneedles (Prausnitz and Langer, 2008).
Transdermal codrugs--carefully controlled design, synthesis and optimization of codrug structures based on chemical stability, enzymatic stability, and solubility. Few
examples exist in the literature concerning optimization and
utility of transdermal codrugs (Cynkowski et al., 2008;
Kiptoo et al., 2006; Kiptoo et al., 2008; Strasinger et al.,
2008).
Micropore lifetime-carefully optimized pharmacokinetic evaluation of micropore lifetime in order to further
evaluate the effect of diclofenac and potentially other COX
inhibitors. Previous studies on micropore lifetime have used
many other visualization evaluation techniques (Kalluri and
Banga, 2009), but only a few have examined pharmacokinetic analysis (Banks et al., 201 O; Banks et al., 2011 ).
Pharmacokinetic evaluation of micropore lifetime is the
most useful and realistic applied method of evaluation.
Drugs that are targets for microneedle-assisted delivery
could impede or enhance the micropore closure rate,
depending on their mechanisms of action. Additionally, very
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few reports occur in the literature describing ways to delay
the micropore closure, so this in itself is an extremely unique
aspect of this project (Banks et al., 2011; Milewski et al.,
2010a).
Transdermal codrugs specifically for microneedle-assisted delivery-the overall goal of the project is something
that has never been done before. The present inventors'
research has shown some of the important aspects of what
type of prodrug/drug is best for microneedle-assisted transdermal delivery (Banks et al., 2010; Banks et al., 2008;
Milewski et al., 201 Oa; Milewski and Stinchcomb, 201 O;
Milewski and Stinchcomb, 2011; Milewski et al., 201 Ob),
but the addition of the codrug that can have optimized
delivery rates as well as duration is very new in drug
delivery research.
Development of an improved 7-day transdermal system
for NTX-this would improve patient compliance and the
side-effect profile, as the depot injection and tablet have
many drawbacks. The translational goal of the research is to
develop an improved dosage form for naltrexone delivery
for addicts and alcoholics. After the proof-of-concept
research is complete, preclinical toxicology tests could be
completed, an IND filed, and a Phase I clinical trial could
begin at the end of three years. By this time, other
microneedle systems should be on the market, so the primary regulatory hurdle would be the safety and efficacy of
the codrug itself. Seven day transdermal patches on the
market are very popular products.
Exemplary Compounds.
Synthesis and testing of the compounds of FIGS. 2A and
2B is now described, and contemplated with regard to other
compounds in FIG. 2. The detailed synthetic methods are in
the Synthetic Schemes provided hereinbelow. These two
compounds have an ester linking naltrexone or naltrexol to
diclofenac. The chemical stability half-life of Compound 2A
in buffer (skin pH 5.0 and skin surface temperature 32° C.)
was around 4.3 days and the enzymatic stability half-life in
the hairless guinea pig plasma was around 6 minutes,
indicating that any intact codrug that reached systemic
circulation would regenerate the parent drugs as soon as it
enters the body.
In both stability studies, regeneration of the parent compounds was observed with the degradation of the codrug.
Compound 2A bioconverted completely in the skin to form
only the parent compounds in the receiver and plasma in the
in vitro diffusion and in vivo studies, respectively. Compound 2A made a very good proof-of-concept drug to test in
vitro and in vivo in order to see if sufficient diclofenac could
be deposited into the skin for therapeutic micropore closure
delay, and also to see if it cleaved in the skin to the parent
compounds. Compound 2B was synthesized next, as the
ester linkage to NTXOL at the 6-0 position has been found
to be more chemically stable than linkage at the 3-0 position
of the phenolic ring. This is another reason to use NTXOL,
because the 6-0 position in NTX is a ketone and not a
hydroxyl that can be easily made into a prodrug. However,
other structures have been proposed to help improve the
chemical stability of the 3-0 phenolic hydroxyl prodrug
linkage, e.g. Compound 2C with the addition of carbons in
between to help slow the hydrolysis, and Compound 2G and
Compound 21 with carbamate and carbonate linkages.
Experimental Design The detailed synthetic are set forth
hereinbelow. All the reactions utilize established reagents
and protecting chemistries. Hydrogen bonding capacity will
be especially important in the design of the codrugs to be
used with the aqueous pores formed by the microneedles.
Molecular size can be somewhat increased in the case of the

microneedle enhancement, as compounds as large as insulin
have been delivered through micropores (McAllister et al.,
2003). However, the present inventors have learned that an
increase in viscosity, roughly correlated with the molecular
weight of a compound, can decrease the diffusion rate
through the microneedle pores (Milewski et al., 2010a;
Milewski and Stinchcomb, 201 O; Milewski and Stinchcomb,
2011; Milewski et al., 201 Ob), therefore polyethylene glycol
(PEG, 11, 12) units will not be increased to over six. Codrug
design can be limited to smaller molecular weights, if the
solubility increase does not overshadow the molecular
weight dependency with microneedle delivery.
The addition of the synthesis of the di-conjugated codrugs
and their comparison with the successful mono-conjugated
codrug moieties is novel. Ester, carbamate, and carbonate
ester linked prodrugs are successful prodrugs, so these
linkages have been maintained. All of the codrug structures
will be optimized to solubilize and permeate through the
aqueous channels created by microneedle delivery. These
microneedle-assisted codrugs will therefore be very hydrophilic, but it is certain that a relatively fast bioconversion
rate will still be an important property of these codrugs so
that the diclofenac can be deposited into the skin. A more
hydrophilic NTX codrug should more readily enter the
microneedle-created pore, and then diffuse to the capillaries
for systemic circulation uptake. More hydrophilic compounds should be taken up by the circulation more readily
than lipophilic compounds, as can be seen in the sustainedrelease injectables body of literature, where changes in
absorption rate correlate with lipophilicity and bioconversion. For example, furanose sugar (17), L-malic acid (18,
20), and phosphate acetic acid ester (15, 16, 19) promoieties
will be studied to determine the flux enhancement with
microneedles.
If the phosphate acetic acid ester is too chemically
unstable, a regular phosphate ester group can be substituted,
and sodium salts of these could also be made. Salts of all of
the compounds are contemplated, as the present inventors
have found that this is the best form to afford an increase in
polarity and aqueous solubility (Banks et al., 2008). The
preferred initial salt form is hydrochloride (Scheme 1), but
lactate and glycolate salts would also be good candidates, for
example. Lactate and glyco late salts are common in topical
preparations at high concentrations. Acetate salts would not
be practical because of potential odor. The acetate, lactate,
and glyco late salts have higher solubilities in the pH range
of interest for topical application, pH 4-6. Higher flux has
been seen from NTX glycolate than NTX HCl through
microneedle-treated skin in vitro, because one can achieve a
higher solubility with glyco late. There is a maximum effect
of solubility on flux when the viscosity outweighs the
solubility effect (Milewski and Stinchcomb, 2011).
The goal is to categorize how the physicochemical properties of these codrug moieties when conjugated at the C-3
phenolic hydroxyl group or at the C-6 (naltrexol) influence
stability and flux measurements, and then to evaluate any
trends that may become evident from physicochemical properties and flux enhancement. Otherwise, physicochemical
properties are altered only by the codrug link in between the
two drugs via pegylation (11, 12), or by changing the
chemical and enzymatic stability with ester, carbonate, carbamate (1-10), and anhydride (13, 14) groups. The addition
of one to four carbon atoms (3-10, 13,14) in between the
ester, carbonate, carbamate, and anhydride linkages is proposed to help improve chemical stability if necessary. Other
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design permutations, besides the 20+ proposed basic structures, are possible once data is gathered and optimization of
flux and stability begins.
A goal is to optimize solubility characteristics, chemical
stability, and bioconversion rates, the most critical prodrug
parameters identified. With these physicochemical attributes
maximized, a therapeutic transdermal drug delivery rate
may be achieved (FIG. 4). The maximum metabolic transformation rate may be limited at a Michaelis-Menten maximum rate, or Vmax, providing the enzymatically labile
codrug is chemically stable enough to cross the micropores
intact. Altering the linkages in the codrugs for polarity and
bioconversion should significantly enhance the transdermal
drug delivery rate. The general codrug design and synthesis
methodology will allow for this flexibility. Many codrugs
are proposed, but data collection will drive the decisions for
which groups of compounds that will/will not be synthesized
and tested, similar to what we have done with the currently
funded proposal. In four years a maximum of 100 compounds could be synthesized. This number of compounds is
well within the capabilities of our synthetic chemistry expertise, as we have already demonstrated in our currently
funded studies.
Calculated codrug physicochemical parameters will
include: molecular weight and volume (Bondi), octanol/
water partition coefficients (Daylight® 4.51 Software),
hydrogen-bonding potentials, relative thermodynamic activity and solubility parameters (Stinchcomb et al., 1995). A
wide range of partition coefficients will provide a sufficient
group of data for QSPR analysis. With every carbon addition
to the alkyl chain, the clogP value usually increases by about
0.5. Generally, the greater a drug's innate tendencies to
dissolve, the more likely it is that the drug can be delivered
at an adequate rate across any membrane, including the skin.
Therefore, experimentally determined prodrug physicochemical parameters will include: octanol/water partition
coefficients, melting points and heats of fusion (important
physicochemical determinants of solubility), and solubilities
in select solvents at 32° C. (buffer and other vehicles used
in the permeation experiments). Skin surface temperature is
approximately 32° C. Difficulties sometimes arise in determining the octanol/water partition coefficients of readily
hydrolyzed esters or extremely hydrophobic drugs. Experimentally determined octanol/water partition coefficients for
some of the codrugs may not be practical, therefore relative
HPLC retention times could substitute for partitioning estimation.
Solubility studies are carried out by equilibrating large
excesses of each drug with the solvent studied. The experiments will be done at skin surface temperature (32° C.). To
hasten the attainment of equilibrium, each slurry will be
continuously shaken or stirred. Samples will be taken,
filtered with an appropriate filter for the solvent, measured
with respect to volume, and either assayed directly by HPLC
or evaporated to dryness and reconstituted for assay. Binding
of the compounds to the filter will be checked to eliminate
the possibility of drug adsorption on the filter and/or filter
casing. All toxic solvents and other chemicals will be
handled with caution, and fume hoods will be used when
appropriate.
The chemical stability of the prodrugs to hydrolysis and
solvolysis at the appropriate temperatures will be determined by measuring concentrations over time in the buffers
and solvents used in the solubility and diffusion studies.
Chemical degradation rate constants will be important in
distinguishing enzymatic degradation from non-enzymatic
degradation. Codrug enzymatic metabolism rate constants

can also be determined in skin homogenates, to ascertain if
the values are useful in the QSPR multiple regression
analysis. The kinetics of codrug enzymatic degradation in
skin homogenates will be done using abdominal plastic
surgery samples. Enzymatic reaction rates will be determined at several different codrug concentrations. The skin is
homogenized (Polytron tissue homogenizer and ground
glass homogenizer fitted with a glass pestle) in HEPESbuffered Hanks' balanced salt solution and the supernatant is
obtained. The enzymatic hydrolysis rates are determined in
the homogenate at 37° C. The codrug and its metabolites
will be obtained by solid-phase extraction, or another appropriate extraction method. Naltrexone and any other metabolite formed will be assayed by HPLC and expressed as moles
of metabolite per minute per milligram of protein. Protein
concentrations in the supernatant will be measured by the
Bradford method. Controls containing only codrug and
HEPES-buffered Hanks' balanced salt solution at 37° C. will
also be monitored to determine non-enzymatic hydrolysis.
The kinetics of codrug enzymatic degradation in skin
homogenates will also be carried out using freshly dermatomed guinea pig skin samples. Immediately after the
animals are euthanized, at the completion of their pharmacokinetic studies, untreated dorsal skin will be harvested for
homogenate metabolism and in vitro diffusion studies.
These metabolism studies will help to quantify any significant differences in the codrug enzymatic reaction rates
between the guinea pig skin and human skin. Additionally,
codrugs may metabolize to other compounds, besides just
the parent drugs. The same procedure can also be done for
pig skin.
Cox inhibitors other than diclofenac are contemplated. In
some cases, a COXl-specific inhibitor may be better, in
which case SC560, valeryl salicylate, mofezolac, FR122047
or another COXl-specific inhibitor can be used. In some
cases, a COX2-specific inhibitor may be better, in which
case, celecoxib, for example, can be used. In some cases, a
less potent nonspecific COX inhibitor could be used, in
which case ibuprofen, ketoprofen, or others are available.
Such COX inhibitors have carboxylic acid moieties, and
chemistry for synthesis does not change substantially. Celecoxib is an exception with an amine functional group, so
different chemistry would be needed (Schemes), as would be
recognized by one of ordinary skill in the art.
Drug penetration, concurrent bioconversion, and COX
inhibitor deposition in skin in vitro with microneedle use.
Compound 2A was tested in the in vitro diffusion study
using Yucatan miniature pig skin with microneedle treatment. A study was conducted with Compound 2A, and a
study was conducted with its HCl salt. FIG. 6 shows the skin
concentrations obtained at different time points. NTX and
diclofenac build to steady-state concentrations as the codrug
hydrolyzes. More diclofenac is retained in the skin because
it is more hydrophobic than NTX, and therefore diclofenac
skin levels are higher than NTX as NTX diffuses into the
receiver compartment.
FIG. 5 shows a diclofenac effective skin concentration
goal, and Compound 2A did not provide that level, however,
the codrug was successful in the hairless guinea pig pharmacokinetic study at keeping open the pores for 7 days, so
it was most likely that more Solaraze (diclofenac) was being
applied than necessary in the initial guinea pig study (FIG.
7). Therefore, a diclofenac skin concentration goal of 0.1
µmol/g of tissue may be all that is needed for effect. At any
rate, the codrug is working as designed, to allow flux of
NTX and retain diclofenac to have an effect on the
micropore closure rate. The present inventors are testing the

10

15

20

25

30

35

40

45

50

55

60

65

US 9,566,341 Bl
23

24

effect of Solaraze (diclofenac) on the micropore closure rate
in human volunteers, and have seen similar results.
FIG. 6 also shows the substantial NTX flux improvement
obtained from the compound salt as compared to the compound free base, consistent with previous data (Banks et al.,
2008). Therefore, the focus will be on codrug salt forms, but
non-salt forms are contemplated as well. This codrug completely hydrolyzed in the skin and only NTX and diclofenac
were detected in the receiver compartment of the in vitro
diffusion study.
Full thickness Yucatan miniature pig skin in vitro studies
to measure diffusion and bioconversion will provide the
most accurate absorption data with microneedle (MN) treatment. It is not necessary to use human skin when using
microneedles, since the pig skin is the same thickness and
the primary route of diffusion is through the MN pores and
not the stratum corneum lipid bilayers. Human skin can be
used in final experiments in order to make sure bioconversion is similar, however, the present inventors are primarily
taking advantage of esterase activity and have not seen a
difference in skin metabolism for this enzyme system in
humans vs. pigs. Pig skin is purchased from Sinclair, or
dermatome from sacrificed pigs used in the pharmacokinetic
studies once the skin has returned to normal. The human skin
in these experiments will be healthy full-thickness (subcutaneous fat removed) abdominal plastic surgery samples
obtained from the Cooperative Human Tissue Network
(CHTN). Universal Precautions (OSHA standards) will be
used when handling the human skin samples, in order to
protect the researcher from any potential harm. IRB
approval is not required by NIH to use non-identified
surgical waste tissue. Microneedle arrays purchased from
1Ox Technology or another manufacturer will be used for all
studies, see letter of support attached.
Guinea pig skin samples will also be used in some in vitro
diffusion and metabolism studies. We want to compare the
transdermal flux rates seen in the animal in vivo data with
animal in vitro data. It will also be important to see the
differences between in vitro guinea pig skin and in vitro
human/pig skin diffusion data. Since we are attempting to
validate our in vitro human skin diffusion data with an in
vivo animal model, we need to know the basic magnitude of
difference in the skin permeabilities among the 3 species, if
any. Micropore closing will not take place in vitro, so these
experiments are used for flux optimization only. Detailed
procedures for diffusion studies are in the publications in the
Appendix and in our other publications. Simple analysis of
variance (ANOVA) will determine significant differences
among the codrugs' flux values.
In some studies it is contemplated to increase the
microneedle array area (and needle number), which can
increase flux, as there is a direct increase in flux with number
of micropores. In some cases a 1 cm2 (50 needles) array is
used, but in other cases a 10 cm 2 array, and potentially an
even larger array could be designed. Since the therapeutic
delivery rate in humans with NTX HCl and 400 micropores
has been achieved, it is believed that achievement of a 7-day
codrug therapeutic flux is highly likely as long as a solubility
similar to NTX HCl is achieved (FIG. 4). Some chemical
stability issues can be resolved by limiting the water in the
final patch formulation that would be used in a microneedle
product.
Characterization of the Pharmacokinetics of the Drugs in
Guinea Pigs and Yucatan Miniature Pigs In Vivo with
Microneedle Use.
A study was done in hairless guinea pigs using diclofenac
(Solaraze) gel applied daily to the micropores with a reser-

voir ofNTX gel on top. NTX plasma profiles after one-time
application of MN's in hairless guinea pigs with one-time
application of0.5 g of 16% NTX.HCl (control) compared to
daily application of 0.5 g of 16% NTX.HCl and approximately 100 µl of Solaraze® topical gel (3% Diclofenac
sodium), 6.7 cm 2 area (n=4) are shown in FIG. 7. Micropore
lifetime was extended up to 7 days in the presence of
diclofenac, but NTX without diclofenac had complete
micropore closure in a similar timeframe to the human study,
2-3 days ((Banks et al., 2011) Appendix).
Compound 2A in its HCl salt form was used to treat 4
hairless guinea pigs. Since flux from this codrug was low,
four patches were placed on the guinea pigs with 7%
saturated codrug gel after a single pretreatment with
microneedles on Day 1. Microneedle treatment at each patch
site contained 100 micropores created by a 1 cm2 50 needle
stainless steel array rotated 90° and inserted twice. A new gel
patch was applied at 3.5 days, as the chemical stability of
Compound 2A is not ideal. Plasma samples were obtained
from a jugular catheter over seven days and analyzed for
drug concentration by LC/MS (Methods). In three out of the
four guinea pigs significant NTX plasma levels were seen
for 7 days, and the pores in one guinea pig closed at 6 days.
Micropores were visualized on the skin of the animals at 7
days by staining the skin with India ink, and the 100 pores
can be seen clearly, including the pattern from the 90°
rotation and re-insertion FIG. 9. Intact codrug was not
detected in the plasma samples. Significant micropore staining was also seen at days 1, 4, 5, 6, and 7.
A goal is to quantitatively characterize the transdermal
delivery of selected naltrexone codrugs in vivo using pharmacokinetic determinants. This will be accomplished by
comparing the kinetic profiles and parameters of intravenous
bolus and topical applications of codrugs using the chronically annulated hairless guinea pig model. Hairless guinea
pigs are a typical animal model used for transdermal delivery experiments. More importantly, guinea pigs have been
shown to have a metabolic profile more similar to humans
than rats or rabbits. Fifteen of the most promising codrug
candidates screened in the in vitro experiments will be fully
characterized in the guinea pig model. Plasma samples will
be analyzed by LC/MS. Detailed procedures for hairless
guinea pig pharmacokinetic studies and data analysis are in
the Appendix publications and many previous publications
from our group (Valiveti et al., 2005a; Valiveti et al., 2005b ).
Five to six animals (guinea pigs and pigs) per treatment
group will be used, and dosing can be done in a crossover
fashion, 2 routes of administration, intravenous vs. percutaneous. A codrug will be considered successful if it can
deliver a similar or greater flux than that achieved in the
human study with NTX HCl (Wermeling et al., 2008). Four
of the most promising codrug candidates screened in the
hairless guinea pigs will be examined in the Yucatan miniature pig, as the thickness of the skin is more similar to
humans, important for microneedle application. This dosefinding proof-of-concept study in the pigs will provide data
that can be included in an IND (Investigational New Drug)
application, and optimizing the dosing of the best codrugs
will help to prepare for pig toxicology studies required for
the IND. ANOVA statistical analysis will be used in order to
determine statistical significance among treatment groups.
Skin infection is not a concern with microneedle treatment and has not been a problem in the animal or human
studies. Skin is swabbed with alcohol prior to microneedle
treatment and formulations can contain microbicidal addi-
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tives, like benzyl alcohol used in our human study (Wermeling et al., 2008). Microneedles are also very sturdy and
do not break in the skin.
LC-MS/NIS conditions: Chromatography colunm used
was Waters Atlantis Hilic Silica 5 µm, 2.lx150withamobile
phase consisting of acetonitrile:buffer 80:20 (v/v). The aqueous buffer consisted of 1 mM ammonium acetate with 0.1 %
acetic acid and 5% MeOH. The injection volume was 20 µ!.
Liquid chromatography was carried out in the isocratic
mode at flow rate 0.3 ml/min with a total run time of 14 min.
The retention times for NDC, NTX, NTXol, DIC and NAL
were as follows: 6.7 min, 9.6 min, 11.4 min, 7.4 min, and 1.6
min, respectively.
The LC-MS-MS system consisted of a HPLC Waters
Alliance 2695 Separations Module, Waters Micromass®
Quattro Micro™ API Tandem Mass Spectrometer. Positive
electrospray ionization was used for detection of all compounds (ESI+), except DIC was analyzed through negative
ionization (ESI-). Multiple reaction monitoring (MRM) was
carried out with the following parent to daughter ion transitions for Compound 2A (NDC), NTX, NTXOL, diclofenac
(DIC) and naloxone internal standard (NAL): m/z
619~342, m/z 342-324, m/z 344~626, m/z 293~250, and
m/z 328~310, respectively. Capillary voltage was 3.5 kV,
RF lens 0.3 V, source temp 130° C., desolvation temperature
270° C. and cone voltage 29 V for NTX, NTXOL and NAL,
18 V for DIC and 38 V for NDC. The collision gas was 19
eV for NTX, 10 eV for DIC and 20 eV for NDC, NTXOL
and NAL. Nitrogen gas was used as a nebulization and
drying gas at flow rates of 50 and 450 L/h, respectively.
Calibration plots were prepared by a linear regression analysis of the ratio of the drug-to-internal standard areas versus
nominal drug concentration. Quadrupoles were set on unit
mass resolution. Based on the peak-to-noise ratios of3:1 for
LOD the following limits of detection were estimated:
NDC<l ng/ml, NTX 3 ng/ml, NTXOL 1 ng/ml and DIC 1
ng/ml. Based on the peak-to-noise ratios oflO: 1 for LOQ the
following limits of quantification were estimated: NDC 3
ng/ml, NTX 10 ng/ml, NTXOL 3 ng/ml and DIC 3 ng/ml.
Vertebrate Animals
The hairless guinea pig pharmacokinetic/irritation and pig
pharmacokinetic experiments will make use of 92 guinea
pigs (male and female IAF hairless; from Charles River
Laboratories); 400-450 g, 6-8 weeks old 12 Yucatan miniature pigs (male and female; from Sinclair BioResources);
-15 kg, 3 months old The proposed experiments will be
conducted as described:
Male and female IAF hairless guinea pigs (400-450 g)
will have surgical implantations of jugular catheters (pharmacokinetic studies). Hairless guinea pigs (n=5-6 per test
compound) are used typically as a small animal model for
topical/transdermal studies. After a 1-2 day recovery period,
animals will be dosed with i.v. or topical drug doses and
blood sampling will be done for up to 96 hours. Blood
removal will not exceed 10% of the animal's total blood
volume. Plasma samples are harvested and analyzed by
LC/MS. Test compounds will be screened in the guinea pigs
and the most successful candidates will be tested in the pig
model. Animals are euthanized at the end of the experiments.
Male and female miniature pigs (-20 kg) will be purchased with two surgically implanted subcutaneous titanium
ports (Access Technology) from Sinclair BioResources.
Sinclair BioResources (USDA#: 43-R-0104 and assurance
#: A4333-01) has staff veterinarians that perform the surgeries according to IACUC protocol (#10402). The surgically implanted pigs remain on-site for 10 days before

shipping to the University of Kentucky. Pigs will be transported and acclimated for 7 days once at the university
before initiation of any pharmacokinetic studies. Miniature
pigs (n=5-6 per test compound) are used typically as a large
animal model for topical/transdermal studies. This breed of
pig is ideal for topical/transdermal studies due to minimal
body hair compared to other breeds. The pig will be placed
in a sling for dosing and sampling. Pigs will be dosed with
topical drug doses after MN application and blood sampling
(24 pre-determined time points) will be done for up to 168
hours. A jacket (Lomir Biomedical Inc) is placed on the pig
to prevent the pig from removing the patches. Lidocaine
(4%) cream is applied to the port area for 10 min prior to
blood collection to minimize discomfort to the pig. Specialized Huber needles are used for flushing and sampling to
maintain the integrity of the ports. Blood removal will not
exceed 10% of the animal's total blood volume. Plasma
samples are harvested and analyzed by LC/MS/MS. Weights
are obtained prior to initiation of studies and monitored
weekly. Animals are euthanized after completion of the
experiments.
Skin irritation in hairless guinea pigs (n=5-6 per test
compound): Erythema from topical drug treatments can be
quantified with a Minolta ChromaMeter (Kobayashi,
Hosaka et al. 1997; Sutinen 2000). A colorimetric measurement of the skin reflection is taken before and after the
topical drug treatment, in order to assess skin irritation
(Kobayashi, Hosaka et al. 1997). Trans-epidermal water loss
(TEWL) measurements will also be taken before and after
patch application, as a relative measure of skin damage.
These two skin measurements are complimentary, and
should provide a good prediction of potential treatment
irritation (Kobayashi, Hosaka et al. 1997; Sutinen 2000).
The irritation potential of the drugs will be evaluated by
taking erythema and trans-epidermal water loss (TEWL)
readings at the induction sites after patch removal. Erythema
from topical drug treatments will be quantified with a
Minolta Chromameter (Kobayashi, Hosaka et al. 1997).
Both chromameter and TEWL reading will be taken before
and after patch removal as a relative measure of redness and
skin damage, respectively. Readings will be taken at 5 min
and thereafter at 1, 2, 24 and 48 h, and daily throughout
treatment. Reactions will be visually graded for erythema at
24 and 48 h after patch removal according to a 5-point
grading scale (0, 0.5 (±), 1, 2, 3). The grades 1, 2 and 3
denote increasing severity of erythema with grades > 1
considered positive. The "0.5 or(±)" grade will be used for
equivocal reactions and will be considered negative.
Responses will be evaluated by two indices, one for incidence and one for severity, for both test and control animals.
The incidence index will be determined by the number of
animals showing a response grade of 1 or greater at either 24
or 48 h out of the total animals in the group. The severity
index will be determined for both 24 h and 48 h response
readings by dividing the sum total of grades in a given group
by the total number of animals exposed.
Pharmacokinetics-Pharmacokinetic parameters will be
determined by fitting the plasma concentration vs. time data
(AUC) during and after drug administration by nonlinear
least squares regression analysis, using commercially available software (SCIENTIST, Micromath, Inc. or WINNONLIN) and a multi-exponential mathematical equation, as
follows:
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where ko is the zero-order administration rate, T is the
administration time and C/s and A./s are fitted parameters
describing the absorption, distribution and elimination rate
constants. The multi-exponential model will be used to
construct smooth curves through the data to compute AUC
and AUMC to the last time point, and will take into
consideration, when necessary, metabolite kinetics (Rowland and Tozer). If the multiexponential model does not
provide an adequate fit for the data, more complex mathematical models will be considered. In some cases we expect
that the codrugs will hydrolyze so rapidly to NTX that
elimination of NTX will not be rate-limited by the bioconversion. The clearance of NTX should be much lower than
the codrugs' clearance values.
The elimination rate constant (k) will be determined from
the terminal log-linear portions of the curves. If the codrug
and NTX exhibit similar terminal log-linear slopes after the
i.v. dose of codrug, then the NTX elimination is rate-limited
by its formation. The fraction (fNTX) of an i.v. dose of
codrug converted to naltrexone will be calculated by:

flux in vitro, one would expect to see the steady-state plasma
concentrations of NTX double (see FIG. 10).
Lag times will be calculated for each individual set of
data. After the topical treatment is removed, the plasma
levels will begin a first-order decline after the "drug reservoir" remaining in the skin is eliminated. The residual levels
of drug left in the skin will be monitored, and an elimination
rate constant will be calculated from the terminal log-linear
portion of the profile. The peak plasma concentration
(Cmax) and time to reach the Cmax (tmax) will be read
directly from the plasma-concentration time profiles.
Preliminary in vitro miniature pig skin studies have been
completed for this project. Animal experiments are also
contemplated. A 1997 article describing a type of artificial
skin was identified. These systems have the same type of
disadvantages as any in vitro testing: the microcirculation
and enzymatic activity of the in vivo skin model is not
represented. It is not possible to study irritation and pharmacokinetics without an in vivo model. Guinea pigs have a
history of use in topical irritation testing. Hairless guinea
pigs are a typical small animal model used for transdermal
experiments. More importantly, guinea pigs have been
shown to have a metabolic profile more similar to humans
than rats or rabbits. Miniature pigs are used typically as a
large animal model for transdermal studies. From previous
experience with animal studies, guinea pigs and pigs can be
tested more than once following a washout period which
helps to reduce the number of animals needed to complete
the necessary studies. Animal studies are necessary to gather
preliminary data in order to determine safety of the compounds and pharmacokinetics before clinical studies are
conducted. Based on experience from previous research and
other researchers, these protocols have been established for
the number of animals required to provide sufficient statistical power to detect significant differences at p<0.05 using
ANOVA and Tukey post-hoc comparisons. The number of
animals used is in confoiinity with good pharmacological
practices.
The University Department of Laboratory Animal
Resources (DLAR) has several full-time veterinarians available that can evaluate the animals if any infection or adverse
reaction occurs. The University operates to comply with the
USDAAnimal Welfare Act (Public Law 89-544) as amended
by PL91-579 (1970) PL94-279 (1976) and 45CFR37618
(6-30-80); Health Research Extension Act of 1985 (Public
Law 99-158); follows the Public health Service Policy on
Humane Care and Use of Laboratory Animals (revised
September 1986); and the Guide for the Care and Use of
Laboratory Animals DHEW (NIH) 85-23 revised 1985. The
facilities' staff involved with institutional animal care and
use is adequately trained and competent and abides by all
provisions set forth by the Animal Welfare Act as well as
other federal, state, and local laws for Animal Welfare. If any
animals have infections or injury, a facility veterinarian will
be consulted and the appropriate treatment will be made or
if necessary the animal will be euthanized. The facility's
veterinarians will be consulted to determine if administering
of analgesics are advised or terminating the study at that
point. The studies are not considered a painful procedure
unless the procedure causes more than slightly or momentary pain or distress in a human being to which the procedure
was applied, this is pain in excess of that caused by
injections or other minor procedures. If the test compounds
used elicit a painful response or maximum scores, the animal
will be humanely euthanized as per the University standard
operating procedures or the animal will receive the appropriate sedatives, analgesics, or anesthetics as per the Uni-
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AUC(NTX~PROIV) refers to the area under the curve of
the naltrexone plasma profile following an i.v. bolus of
codrug. AUC(PRO~PROIV) refers to the area under the
curve of the codrug plasma profile following an i.v. bolus of
codrug. The peak plasma concentrations (Cmax) after the
i.v. bolus doses of the drug will be used to determine the
initial volume of distribution by the following equation:
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Noncompartmental pharmacokinetic determinants calculated will be total clearance (CL=[dose]/AUC), volume of
distribution at steady-state (Vss=dosex[AUMC/AUC 2 -T/
(2xAUC)]), and MRT (MRT=AUMC 0 _jAUC 0 _=-T/2).
(AUC=Area under the concentration vs. time curve;
AUMC=Area under the first-moment-time curve;
MRT=Mean residence time)(Gibaldi and Perrier). The percutaneous absorption data from rapidly skin-converted codrugs should provide a plasma concentration time profile that
exhibits zero-order delivery to an average steady-state level
(Css) of parent drug.
The average transdermal codrug absorption rate R should
also be equal to:

C,,Vk
R=-fNrx

Where Css, V, and k are parent drug values. After removal
of the topical codrug treatment, the elimination would be
controlled by the compound with the longer elimination
half-life, in some cases parent drug. Statistical analyses for
group comparisons will be evaluated by ANOVA, followed
by Tukey post-hoc testing for individual group differences.
Differences will be considered significant when p<0.05.
Changes in flux enhancement that we have seen in the in
vitro studies should be mimicked in the in vivo studies. For
example, if a codrug provides a two-fold increase in NTX
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versity standard operating procedures. All surgical and tissue collection procedures are conducted under general
anesthesia.
All animals are acclimated 7 days prior to initiation of the
studies. All animals are judged to be healthy prior to
utilization in the study. Each guinea pig will be housed
individually in a plastic cage with access to two water bottles
and food. The animals will be fed a standard guinea pig diet
daily ad libitum. Aseptic surgery will be performed on the
guinea pigs. The animals will be fasted four hours prior to
surgery. Guinea pigs will receive pre-operatively glycopyrolate (0.02 mg/kg, sc) and buprenorphine (0.05 mg/kg, sc).
Guinea pigs will be anesthetized with ketamine (100 mg/kg,
ip) and xylazine (8 mg/kg, im). Additional ketamine and
xylazine is administered as needed. A sterile catheter will be
inserted into the jugular vein. All catheters will be tunneled
to the back, secured, and plugged. Intraoperative monitoring
of the animal's condition will include respiration, heart rate,
and response to stimulation. Post-op the guinea pigs will be
given buprenorphine (0.4 mg/kg, sc) for analgesia and an
antibiotic (fluoroquino lone; 5 mg/kg, sc) if infection occurs.
Each pig will have a ten square foot pen with free access
to fresh water. The animals will be fed a standard pig diet
twice daily. Pigs will be restrained in a sling during blood
sample draws from the chronically implanted catheter. If the
pigs are kept in the sling for several hours, they will have
access to water. Pig acclimation to the sling for several hours
at a time will be done during the first week after the animals'
arrival. The pigs will be monitored for undue stress from the
restraint. For the previously described procedures, Yucatan
miniature pigs will be momentarily restrained for procedures
and dosing and then will be returned to their respective cages
for observations. Lidocaine (4%) cream is applied to the port
area for 10 min prior to blood collection to minimize
discomfort to the pig.
Irritation readings in hairless guinea pigs are monitored at
5 min and thereafter at 1, 2, 24 and 48 h after application.
Reactions will be visually graded for erythema at 24 and 48
h after patch removal.
Observations are made at least once daily for the remainder of the studies. Hairless guinea pigs and miniature pigs
are monitored at each time point blood samples are obtained
for pharmacokinetic studies and at least once daily for the
remainder of the studies. Daily weights and rectal temperatures are obtained from the guinea pigs. Biweekly weights
and rectal temperatures are obtained from the miniature pigs.
Guinea pigs and pigs will be housed individually. All
animals will be fed a standard diet and offered ad libitum
water.
For the previously described procedures, guinea pigs will
be momentarily restrained for procedures and dosing and
then will be returned to their respective cages for observations. If any animals have infections or injury, a facility
veterinarian will be consulted and the appropriate treatment
will be made or if necessary the animal will be euthanized.
The facility's veterinarians will be consulted to determine if
administering of analgesics are advised or terminating the
study at that point. The studies are not considered a painful
procedure unless the procedure causes more than slightly or
momentary pain or distress in a human being to which the
procedure was applied, this is pain in excess of that caused

by injections or other minor procedures. If the test compounds used elicit a painful response or maximum scores,
the animal will be humanely euthanized as per the University standard operating procedures or the animal will receive
the appropriate sedatives, analgesics, or anesthetics as per
the University standard operating procedures. All surgical
and tissue collection procedures are conducted under general
anesthesia. The facilities' staff involved with institutional
animal care and use is adequately trained and competent and
abides by all provisions set forth by the Animal Welfare Act
as well as other federal, state, and local laws for Animal
Welfare.
There will be no unnecessary duplication of studies and
that all reasonable efforts will be made to minimize animal
exposure to pain, stress, and discomfort whenever possible.
All protocols are approved by the University Institutional
Animal Care and Use committee. All personnel handling
laboratory animals are required to successfully complete a
basic training program (Education and Training in the Care
and Use of Laboratory Animals: A Guide for Developing
Institutional Programs, National Academy Press, 1991).
Additional species and procedure specific training programs
are provided through the DLAR training program and the
AALAS Learning Library is available to all University
personnel using vertebrate animals in research and teaching.
If the test compounds used elicit a painful response or if
maximum scores, the animal will be humanely euthanized as
per the University DLAR's standard operating procedures if
the appropriate sedatives, analgesics, or anesthetics would
not alleviate the pain or distress of the animal. If the animal
has a weight loss of greater than 10%, the animal will be
humanely euthanized. At the end of the experiments, guinea
pigs (minimum dosage of 0.22 mL/kg of body weight) will
receive Beuthanasia-D Special (pentobarbital sodium and
phenytoin sodium) overdose. At the end of the experiments,
pigs will be sedated with ketamine (20 mg/kg, im) and
euthanized with an intravenous overdose of Beuthanasia-D
Special as approved by theAVMA panel on Euthanasia. This
type of euthanasia is simple and routinely used for guinea
pigs and pigs at the animal research facilities.
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tected codrug. Boe-protected diclofenac-naltrexone codrug
(I) will be dissolved in I, 4-dioxane and treated with
equimolar 2M HCl in dioxane to give hydrochloride salt of
diclofenac-naltrexone (24) after I h reflux. To determine
whether acid groups can be readily attached to naltrexone or
naltrexol, we performed a pilot experiment using Boe- or
Fmoc-protected amino acids, successfully yielding amino
acid-coupled naltrexone or naltrexol.
Codrug-1: Sodium salt of diclofenac was dissolved in I: I
(Ethyl acetate:Water) mixture and acidified with concentrated hydrochloric acid. Organic layer was separated and
aqueous layer treated with ethyl acetate two times. Combined organic layer was dried on anhydrous sodium sulfate
and rotary evaporated to remove reaction solvents.
Diclofenac free acid was activated with DCC (N, N'-Dicyclohexyl carbodiimide)) and DMAP (4-Dimethylaminopyridine) in dry tetrahydrofuran. After two hours, equivalent
naltrexone was added in dry tetrahydrofuran. Combined
reactants were allowed to stir over night under nitrogen
atmosphere. After completion of the reaction, solvents were
removed under reduced pressure and reaction crude mixture
purified by flash silica gel column chromatography eluting
with 80% ethyl acetate and 20% cyclohexane and codrug-1
was obtained in 56% (Scheme-I) yield. The codrug-1 was
dissolved in I, 4-dioxane and an equimolar amount of 2M
hydrochloric acid in dioxane was added and refluxed for 1.5
hrs, and precipitated with hexanes to get hydrochloride salt
codrug-24 (Scheme-I).
1
HNMR (CDC1 3 , 300 MHz): ll 6.57 (d, lH), 6.60 (d, 2H),
6.75 (d, lH), 6.93 (m, 2H), 7.19 (t, lH), 7.29 (m, 2H)
13
CNMR(CDC1 3 , (300 MHz): ll 4.22, 4.41, 9.77, 23.31,
31.09, 31.59, 36.45, 38.50, 43.75, 51.01, 59.48, 62.15,
70.28, 90.93, 118.75, 119.52, 122.45, 123.05, 124.19,
124.31, 128.30, 128.97, 129.73, 130.38, 130.64, 131.31,
132.63, 138.09, 142.92, 147.77, 169.98, 207.67
HRMS: Calculated for C 34H320 5 N 2 Cl 2 618.1688 and
found 618.1697.
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Commercially available sodium salt of diclofenac (21)
will be protected with Boe group using Boe anhydride to
prevent intramolecular cyclization reaction. After overnight
reaction at room temperature, Boe-protected diclofenac (22)
will be obtained by extraction using diethyl ether and cold
IN HCI. Compound 22 and naltrexone (23) will be coupled
using conventional coupling approach to yield a Boe-pro-
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Naltrexol (24) was synthesized with a reported process
(Decosta, Iadarola et al. 1992) and phenolic hydroxyl group
was protected with benzyl bromide to get compound (25)
(Pelotte, Smith et al. 2009). Benzyl protected naltrexol (25)
will be coupled with Boe-protected diclofenac acid (22) to
provide naltrexol-diclofenac codrug-(2). This codrug on
treatment with hydrochloric acid produced the salt form of
codrug-(27).
Codrug-2: Diclofenac acid was dissolved in dry THF and
activated with DCC/DMAP for about two hours on an ice
bath. Later on 3-0Bn-6-~-naltrexol was added drop wise in
dry THF, and reaction mixture allowed to stir over night
under nitrogen atmosphere. Completion of the reaction was
monitored with TLC and crude compound washed with
ethyl acetate to get rid of dicyclohexy urea and purification
on silica column gave titled compound-2 (Scheme-2) in 60%
yield.

20

Cl

y:Cl(JYO

-continued
1. 23

_,..Boe

25

0

~I

II
~OH

~

30

DCC

N

NC!

DMAP
2. H+

0
30

~NH

0

ci~o00
u~

35

Chemical Formula: C 34H34Cl 2 N 2 0 5 , Exact Mass: 620.18,
Molecular Weight: 621.55

N'7

1

H-NMR (CDC1 3 , 500 MHz) ll 7.34-7.30 (m, 2H), 7.267.7.24 (m, lH), 7.16-7.07 (m, lH), 6.97 (s, 2H), 6.88-6.85
(m, lH), 6.70-6.68 (m, lH), 6.56 (m, lH), 4.74-4.62 (m,
2H), 3.85 (s, 2H), 3.08 (s, lH), 3.02-2.98 (m, lH), 2.64-2.55
(m, 2H), 2.36-2.23 (m, 3H), 2.12-2.07 (m, lH) 2.01-1.63 (m,
lH), 1.79-1.76 (m, lH), 1.59-1.57 (m, lH), 1.46-1.40 (m,
2H), 1.25 (m, 3H), 0.87-0.83 (m, 2H), 0.83-0.51 (m, 2H),
0.11 (s, 2H)
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Commercially available benzyl protected hydroxy acids
(28) will be used in this synthesis. If not required, starting
material will be synthesized according to reported procedures (Sunazuka, Tsuzuki et al. 1992). Precursor (29) will be
obtained on DCC coupling ofbenzyl protected hydroxy acid
(28) and Boc-diclofenac acid (22). Hydrogenation of compound 29 followed by coupling with naltrexone (23) will
give codrug-(3).
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Parallel protocol will be used to make codrug-( 4). Debenzylation via hydrogenolysis of intermediate (31) will give
iarget codrug-( 4).
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Boe protected amino acids (32) will be used to make
codrugs-(5) and -(6) as outlined in schemes-5 and -6. Once
Boe protected amino acid is attached to naltrexone (23) with
DCC mediated coupling to get (33), Boe group will be
removed with well-known deprotection methods. Amino
compound (34) and naltrexone (23) will be coupled to yield
codrug-(5).
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To make codrug-(6) with ester and amide link, benzyl
protected naltrexol (25) will be used. Debenzylation of (37)
will yield codrug-(6).
Scheme-7
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Mono benzyl amine protected starting materials will be
used to produce amide-amide linked spacer codrug-(7).
Unavailable starting amino compounds will be synthesized
according to published methods (Krivickas, Tamanini et al.

2007). Triphosgene treated naltrexone (Hamad, Kiptoo et al.
2006) (23) on action with (38) will give compound 39
(Scheme 7). As outlined in scheme-7, codrug-(8) will be
synthesized by hydrogenation of compound 39.
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0-mono benzyl protected dials (40) will be used as
starting materials for the projected synthesis or materials
will be synthesized according to literature protocols (G.
Venkateswar Reddy 2009), (Simas, Pais et al. 2003). DCC
mediated union between diclofenac acid (22) and 0-mono
benzyl dial (40) will give derivative-(41 ). This derivative

25

(41) on debenzylation gives composite (42) and on followed
reaction with triphosgene treated benzyl protected naltrexol
(Hamad, Kiptoo et al. 2006) (25) will give a new intermediate (43). Hydrogenolysis of (43) will give codrug-(9)
(Scheme 8). Codrug-(10) will also be synthesized by using
naltrexone (23) and triphosgene reagent.
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Pegylated codrugs-(11) and -(12) are designed based on
reported studies (Bonina, Puglia et al. 2001) and will be
synthesized as described in scheme-9. To avoid potential
toxicity, the peg spacers will be used from n=4. Mono
0-benzyl PEG spacer will be synthesized with small adaptation per the reported protocols (Bellouard, Chuburu et al.

30

1999), (Jiang and Yu 2008). PEG hydroxyl acid (44) on
DCC coupling with naltrexone (23) will give peglylated
naltrexone compound (45) and on further DCC coupling
with diclofenac acid (22) will give PEG linked codrug-(11 ).
By using benzyl protected naltrexol (25) PEG spacer linked
diclofenac-naltrexol codrug-(12) will be synthesized.
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Anhydride codrugs are proposed based on research
articles of diclofenac anhydride prodrugs (Mizrahi and
Domb 2009). Mono benzyl protected dicarboxylic acids (47)
will be used for synthesis of codrugs-(13) and -(14) as
outlined in scheme-10. Debenzylation and DCC mediated
coupling with naltrexone (23) will give codrug-(13). If
starting materials are not commercially available they will
be synthesized according to the following reference (Ballard, Richards et al. 2008). Diclofenac derivative (49) on
DCC coupling with benzyl protected naltrexol (25) will give
intermediate (50). This compound on hydrogenolysis will
give codrug-(14).
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To increase the aqueous solubility, several codrugs are
proposed in schemes-11-14. These codrugs are planned
based on the following published research (Du, Hong et al.
2007), (Rouquayrol, Gaucher et al. 2001), (Baba and Yoshioka 2006). Water solubilizing phosphate, amino acid and
L-malic acid moieties will be attached to phenolic hydroxy
group of naltrexone (23) and aliphatic hydroxyl group of
naltrexol (24). Naltrexol derivative in scheme-12 will be
synthesized according to reported synthesis (Nelson, Davis
et al. 1994).

Scheme-12
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Final codrugs and all intermediate compounds will be
completely characterized by 1 HNMR, 13 CNMR spectroscopy and mass spectrometry. All the codrugs will be con-

verted to hydrochloride, glycolate and lactate salts according
to mentioned reference (B. S. Somashekar 2005).
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Celecoxib (60) will be reacted with different cyclic anhydrides to make intermediate (61), similar to some published
protocols (Mantarosie, Coman et al. 2008), (Paun, Stere et
al. 2008). Terminal carboxylic acid free compound (61) will
attach to naltrexone (23) or benzyl protected naltrexol (25)
to get target codrugs-21 and 22 (Scheme-14).
Example 2
The compound of FIG. 2U (Compound 2U) is studied.
Stability: The chemical stability of the compound in the
pH 5.0 acetate buffer (0.3M) was 3.9±0.56 days and the
enzymatic stability in the hairless guinea pig (HGP) plasma
was 6.4±0.84 min (n=3) indicating that the compound would
be degraded to regenerate the parent drugs as soon as it
enters the body. In both the studies regeneration of the
parents was observed with the degradation of the compound.
In vitro: The first in vitro experiments showed that the
compound degraded in the skin to regenerate back the parent
drugs even at 24 hours and amount of parent drugs from the
compound increased with time. Steady state flux was
obtained both from naltrexone and diclofenac of 0.42±0.12
nmol/(cm 2 /hr) and 0.19±0.06 nmol/(cm2 /hr) respectively
(FIG. 14A). The naltrexone flux was significantly higher
compared to diclofenac (p<0.05). The skin concentration
data is shown below in FIG. 14B. n=3 for flux calculation;
n=2 for skin concentration studies at 36 and 48 hr timepoint
and n=3 for 12 and 24 hr. (FIG. 14B).
The flux of naltrexone from the hydrochloride salt form of
the compound was 5.42±1.5 nmol/(cm2 /hr) compared to
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0.42±0.12 nmol/(cm2 /hr) (p<0.005). The skin concentration
for both naltrexone and the compound also increased. n=4
for the flux calculation. FIG. 15. So the flux increased by
about 13 times using the salt form of the compound over the
free base form.
Precipitation issues were observed with purely aqueous
donor, so an in vitro formulation development experiment
was carried out by varying the amount of PG in the donor.
10%, 25% and 50% PG was used with the salt form and it
was observed that while there was no significant difference
in flux between the aqueous formulation and 10% PG
containing formulation (p<0.05), but flux decreased significantly for higher concentrations of PG. The data was compared using one way ANOVA and Tukey's posthoc analysis
for pairwise multiple comparisons. The 10% PG containing
formulation was hence chosen for in vivo studies. All
experiments were carried out with a saturated donor solution.
In vivo experiments. The pores can be clearly visualized
with gentian violet in FIG. 15 (A) immediately following
MN treatment. In panel (B) the pores cannot be visualized
at day 4 (96 h) pores treatment with MN followed by
application of NTX HCl gel under occlusion. Pores can be
visualized by India ink staining in panel C where the
hydrochloride salt form of the compound was used following MN treatment indicating that the pores can stay open up
to a 7 day time point.
The compound of FIG. 2V (Compound 2V) is studied.
Stability A chemical stability study was done for the
compound 2 in 0.3M acetate buffer pH 5.0 at 32° C. The half
life was approximately 56.3±9.5 days
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In vitro experiments The compound was tested in a 10%
PG containing saturated donor formulation for in vitro flux
and a naltrexol flux of approximately 0.29±0.09 nmol/cm2 /h
was obtained from the compound compared to 3.07±0.27
nmol/cm2 /h naltrexol flux from 10% PG containing saturated naltrexol formulation. See FIG. 18.
The compound of FIG. 2W (Compound 2W) is studied.
A chemical stability study was done for the compound
2W in 0.3M acetate buffer

bottom of the rubber ringed barrier to maintain mt1mate
contact with the skin and prevent evaporation of the 300 µL
gel formulations.
Gel Formulations
4% w/w gels were prepared with the hydrochloride salt
form of the compound for in vivo studies. Hydrochloride salt
gels were formulated by dissolving 4% compound salt in
propylene glycol: acetate buffer at pH 4.8-10:90 and 3.0%
hydroxyethylcellulose polymer. As the polymer was dissolved over a 30 minute period, the solution was continuously stirred to ensure salvation as well as to initiate
polymerization. The solution was stirred still a viscous gel
resulted and then left at room temperature for 11/2 to 2 hours
to remove bubbles and ensure complete polymerization. The
gel was saturated with excess solid and therefore was a
cloudy gel.
Pharmacokinetic Animal Studies
Hairless IAF guinea pigs (Charles River) weighing 350650 g were used for these studies. All animal studies were
in accordance with the institutional guidelines and approved
by the University of Kentucky IACUC. Surgical procedure
was performed to canulate the jugular vein. Blood samples
(0.3 mL) were drawn from the jugular vein at regular time
intervals for the time studied. MN treated animals were first
cleaned topically with isopropyl alcohol, and two 50 MN
arrays were then manually applied to each dose site. For MN
treated GPs, four 0.3 mL gel doses were applied to the dorsal
region of the hairless guinea pigs at 4 sites to obtain steady
state plasma levels. After application of the gel the skin was
occluded with the patch and occlusive tape was applied to
prevent evaporation of the formulation Blood samples were
obtained for 7 days while the patch was changed with new
formulation at 3.5 days. The blood samples were immediately centrifuged at 10,000xg for 3 min; plasma was separated and stored at - 70° C. until analysis.
Staining
The patches were removed at predetermined time points
and the site was cleaned with sterile gauze. Gentian violet/
India ink was applied as the dyeing agent at the MN treated
sites and allowed to dry before excess dye was removed with
ethanol and gauze. Both the dyes stain the viable epidermis
but not the intact SC. Hence, a grid is observed only in the
presence of micropores in the skin, no staining is observed
in its absence immersing the skin pieces in ACN overnight
in a water bath shaker at 32° C. The donor was removed
from the top of the skin at the end of the study and analyzed
by direct injection onto HPLC after suitable dilution using
ACN.
HPLC analysis. Quantitative analysis of naltrexone,
diclofenac and the compound concentrations in all samples
were carried out using a HPLC assay. The receiver samples
were concentrated 10 fold with acetonitrile by evaporating 1
ml of the solution under nitrogen and reconstituting in 100
µl of ACN and injected into the HPLC. The skin samples
were directly injected onto the HPLC. The HPLC system
consisted of a Waters 717 plus autosampler, a Waters 600
quaternary pump, and a Waters 2487 dual wavelength absorbance detector with Waters Empower™ software. A Brownlee (Wellesley, Mass., USA) C-18 reversed phase Spheri-5
µm column (220x4.6 mm) with a C-18 reversed phase guard
column of the same type (15x3.2 mm) by Perkin Elmer®
was used with the UV detector set at a wavelength of 215 nm
or 280 nm. The mobile phase consisted of 70:30 (v/v)
ACN:(0.1 % TFA with 0.065% I-octane sulfonic acid
sodium salt, adjusted to pH 3.0 with TEA aqueous phase).
Samples were run at a flow rate of 1.5 ml/min with a run
time of 8.5 min. The injection volume used was 25 µl for

Chemical stability
(days)
Enzymatic stability
(minutes)

Compound 2A

Compound 2B

Compound 2C

3.9 ± 0.56

56.3 ± 9.5

37.08 ± 1.22

6.4 ± 0.84 min

Methods:
For all in vitro experiments female Yucatan minipig skin
(6 months old) were used. Skin sections were obtained by
removing the subcutaneous fatty tissue by scalpel dissection,
and were stored at -20° C. A PermeGear flow-through
(In-Line, Riegelsville, Pa., USA) diffusion cell system was
used for the skin permeation studies. Skin used for
microneedle treatment was placed on a wafer of polydimethylsiloxane polymer, which mimicked the underlying
mechanical support of tissue because of its comparable
structural flexibility and elasticity.
The skin was pierced 20 times with an array containing 5
MN (i.e., to make a total of 100 individual and non-over
lapping piercings) before mounting the skin in the diffusion
cell for the treatment group. The insertion of MN into skin
was carried out manually by applying gentle finger pressure
followed by instantaneous removal. MN's were distributed
evenly within the 0.95 cm2 area of skin and could easily be
visualized after each 5 MN insertion, as to prevent reapplication in the same area. Single MN array of 5 were used
simply out of ease for the experimental procedure. If any
damage to an MN section was observed the section was
replaced. Cells containing MN treated skin showed no
presence of receiver solution back flow into the donor
compartment. Untreated skin samples were simply placed in
the diffusion cells. Diffusion cells were kept at 32° C. using
a circulating water bath. Data were collected using skin from
a single pig 3-4 cells for the MN treated formulations.
The physiological receiver solution was water adjusted to
pH 7.4 containing 20% ethanol, and the flow rate was
adjusted to 1.5 ml/h. Each cell was charged with 0.25 ml of
the donor in the donor compartment of the chamber. The
diffusion cells were covered with a stopper to prevent
evaporation. Samples were collected from the receiver compartment in six-hour increments over 48 h or for the length
of the treatment. All samples were stored at 4 ° C. until
analyzed by HPLC.
The skin samples at the end of the treatment period was
removed, the treatment area was cut out with a scalpel and
diced into small pieces. Extraction of drug was done by The
transdermal occlusive protective covering patches were fabricated by sandwiching a rubber ringed barrier to create a
reservoir between a drug-impermeable backing membrane
(Scotchpak™ #1109 SPAK 1.34 MIL Heat Sealable Polyester Film) and anARcare® 7396 adhesive around the edge
of the rubber spacer. The impermeable backing laminate was
adhered to the rubber retaining ringed barrier with 3M™
double sided tape. Finally, ARcare® 7396 was placed on the
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receiver samples and 100 µl for the skin samples. The
but not the intact SC. Hence, a grid is observed only in the
retention time of naltrexone was 2.3 minutes, diclofenac was
presence of micropores in the skin, no staining is observed
3.5 minutes and compound was 6.5 minutes. Samples were
in its absence.
analyzed within a linear range of standard curve for all the
three compounds from 100-10000 ng/ml. The standard soluExample 3
tions exhibited excellent linearity over the entire concentration range employed in the assays. For the plasma samples
Microneedle enhanced transdermal drug delivery enables
the mobile phase consisted of 50:50 (v/v) ACN:(0.1 % TFA
the transport of a host of molecules that cannot be delivered
with 0.065% I-octane sulfonic acid sodium salt, adjusted to
across the skin by passive diffusion alone. However, the skin
pH 3.0 with TEA aqueous phase). Samples were run at a 10 being a self-regenerating organ heals itself and thus prevents
flow rate of 1.0 ml/min with a run time of 37 minutes and
delivery of molecules across micropores for a seven day
injection volume of 10 µ!.The retention time for naltrexone
time period, the ideal transdermal delivery goal. Hence, it is
was 3.3 minutes, diclofenac was 16 minutes and compound
necessary to employ a second drug molecule, a cyclooxywas 33 minutes. Compound 2B and Compound 2C were
genase inhibitor to enhance pore lifetime by decreasing
detected using the same assay. The retention times were 5.8 15 inflammatory response following microneedle treatment. A
and 4.3 minutes respectively.
codrug approach using a 3-0-ester codrug of naltrexone, the
In vivo experiments. Fabrication of transdermal patches
model drug with diclofenac, a cyclooxygenase inhibitor was
Transdermal Patches.
tested in vitro as well as in vivo to look at stability,
The transdermal occlusive protective covering patches
bioconversion as well as permeation. The results indicate
were fabricated by sandwiching a rubber ringed barrier to 20 that the approach could be useful for transdermal drug
create a reservoir between a drug-impermeable backing
delivery of naltrexone from a single patch for a week, but
membrane (Scotchpak™ #1109 SPAK 1.34 MIL Heat Sealstability and solubility enhancement will be required before
able Polyester Film) and anARcare® 7396 adhesive around
it can deliver therapeutically relevant levels of the drug. The
the edge of the rubber spacer. The impermeable backing
skin concentration of diclofenac was high enough to keep
laminate was adhered to the rubber retaining ringed barrier 25 the pores open in vivo in a hairless guinea pig model as
with 3M™ double sided tape. Finally, ARcare® 7396 was
evidenced by pore visualization studies.
placed on the bottom of the rubber ringed barrier to maintain
INTRODUCTION
intimate contact with the skin and prevent evaporation of the
300 µL gel formulations.
Gel Formulations
30
Transdermal drug delivery is a potential alternative route
4% w/w gels were prepared with the hydrochloride salt
for a host of drug molecules that are difficult to deliver via
form of the compound for in vivo studies. Hydrochloride salt
the oral or parenteral route. It avoids first pass effects,
gels were formulated by dissolving 4% compound salt in
hepatotoxicity, gastric irritation issues as well as needlephopropylene glycol: acetate buffer at pH 4.8-10:90 and 3.0%
bia. However, only small, lipophilic molecules can be delivhydroxyethylcellulose polymer. As the polymer was dis- 35 ered by passive diffusion alone across the stratum comeum
solved over a 30 minute period, the solution was continu(SC), the main barrier to transdermal drug delivery (Prausously stirred to ensure salvation as well as to initiate
nitz, et al. (2004), Prausnitz and Langer (2008)). Hence,
physical and chemical enhancement techniques are being
polymerization. The solution was stirred still a viscous gel
used to enhance the number the molecules that can be
resulted and then left at room temperature for 11/2 to 2 hours
to remove bubbles and ensure complete polymerization. The 40 delivered via this route. Physical enhancement techniques
gel was saturated with excess solid and therefore was a
include iontophoresis, electroporation, low frequency ultracloudy gel.
sound and microneedle (MN) enhanced delivery. Chemical
Pharmacokinetic Animal Studies
enhancement techniques include chemical enhancers and the
Hairless IAF guinea pigs (Charles River) weighing 350prodrugs/codrugs approach. In this study MN enhanced
650 g were used for these studies. All animal studies were 45 delivery was combined with a codrug approach to develop
in accordance with the institutional guidelines and approved
a seven day sustained release patch system. MN is a miniby the University of Kentucky IACUC. Surgical procedure
mally invasive physical enhancement technique. The
was performed to canulate the jugular vein. Blood samples
method adopted is the "poke and patch" approach3 where
(0.3 mL) were drawn from the jugular vein at regular time
solid stainless steel MN arrays are used to create micropores
intervals for the time studied. MN treated animals were first 50 (also referred to as micro channels) across the SC. The MN
cleaned topically with isopropyl alcohol, and two 50 MN
is then removed and a matrix/reservoir type patch is applied
arrays were then manually applied to each dose site. For MN
to deliver drugs through the micropores. Pain associated
treated GPs, four 0.3 mL gel doses were applied to the dorsal
with the application of these MNs is also negligible when
region of the hairless guinea pigs at 4 sites to obtain steady
compared to a hypodermic needle (Kaushik, et al., (2001),
state plasma levels. After application of the gel the skin was 55 Gill, et al. (2008)) which could potentially lead to better
occluded with the patch and occlusive tape was applied to
compliance, one of the major drawbacks of addiction
prevent evaporation of the formulation Blood samples were
therapy (O'Malley, et al. (1992)).
obtained for 7 days while the patch was changed with new
Naltrexone (NTX), the model compound (M.W of341.41,
formulation at 3.5 days. The blood samples were immedilog P of 1.8) is one of the leading FDA approved pharmaately centrifuged at 10,000xg for 3 min; plasma was sepa- 60 cotherapy for alcohol addiction. It is a µ-opioid receptor
rated and stored at 70 g C until analysis.
antagonist and is known to decrease alcohol craving in
Staining
recovering addicts. The drug exerts its mechanism of action
The patches were removed at predetermined time points
by attenuating the ethanol induced stimulation of the
and the site was cleaned with sterile gauze. Gentian violet/
mesolimbic-dopaminergic pathway (Lee, et al. (2005), Swift
India ink was applied as the dyeing agent at the MN treated 65 (2010)). Currently, NTX is marketed as a 50 mg once daily
sites and allowed to dry before excess dye was removed with
oral formulation, Revia® (Naltrexone Hydrochloride). This
ethanol and gauze. Both the dyes stain the viable epidermis
has compliance issues in addicts Hulse and Basso (2000),
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Volpicelli (1997). It also has an oral bioavaibility ranging
from 5-40% and is associated with side effects like hepatotoxicity, nausea and vomiting (1996, PDR. 2d Ed, New
Jersey, Medical Economics). The intramuscular injectable
28 day controlled release formulation of NTX; Vivitrol™
was approved by the FDA in 2006. Injection site reactions
and difficulty of removal in case of emergency opiate
treatment in addition to the above are some of the major
drawbacks of this dosage form (Alkermes, Vivitrol Alert).
6-~ naltrexol is the major metabolite of NTX and has a
higher half-life of 13 hours in plasma compared to that of 4
hours for NTX. It has been shown to be an effective therapy
for alcohol abuse as well (McCaul, et al., (2000)).
NTX cannot be delivered in relevant therapeutic concentrations transdermally by passive delivery alone. Some of
the earlier efforts in the laboratory have looked at delivery
ofNTX via the prodrugs and codrugs approach. The results
indicated that although flux enhancement was achieved in
vitro in some cases, the flux enhancement was not enough to
deliver the molecule in therapeutically relevant concentrations in vivo (Hammell, et al. (2004), Haranath, et al. (2005),
Kiptoo, et al. (2008)). Using MN it has been shown both in
vitro as well as in vivo that NTX can be delivered in the
lower therapeutic range of 2 ng/ml Banks, et al. (2008),
Wermeling, et al. (2008), Verebey, et al. (1976)). However,
one of the issues with this approach is that the micropores
begin to close between 48-72 hour (Wermeling, et al. (2008),
Banks, et al. (2010), Kalluri and Banga (2011 ). Therefore, in
order to develop a 7 day patch system, pore lifetime
enhancement techniques need to be employed along with
MN for successful therapy.
Different techniques can be used to delay barrier recovery
after MN treatment. The skin is a self-regulatory organ and
employs different methods for recovery after assault. Cutaneous wound healing itself consists of multiple phases,
inflammatory response being the first step. Increased synthesis and secretion of lamellar body contents and transformation into bilayer is also a part of the recovery process
(Feingold (2002), Feingold, et al. (2000), Menon, et al.
(1992). Occlusion alone can also delay the recovery process
by decreasing the water flux across the barrier, one of the
major signals for recovery of structure and function
(Grubauer et al. (1989)).
There are several literature reports indicating the increase
in expression of both COX-I and COX-2 following damage
to the skin and the role of, both the enzymes in cutaneous
repair (Pecker, et al. (2007), Davidson and Breyer (2003),
Muller-Decker, et al. (2002), Futagami, et al. (2000)).
Diclofenac (DIC) is a NSAID that nonselectively inhibits
both COX-I and COX-2 thereby preventing formation of
downstream products like prostaglandins and thromboxane,
thus decreasing inflammation. It is currently available on the
market as an oral as well as topical formulation and is the
first choice ofNSAID for this project. Previous experiments
showed that by daily application of Solaraze Gel® (3%
diclofenac sodium, 2.5% hyaluronic acid) after one time
application of MN was able to deliver NTX over the seven
day time period in hairless guinea pig (HGP) (Banks, et al.
(2011 ). Daily application is irrational for a patch system and
co formulating the drugs in high concentration at a pH
optimum of 5 (pH of the outer layer of the skin is 4.5-5.5)3 2
is difficult because the drugs have different physicochemical
properties (FIG. 11). This leads to the codrug approach. The
3-0-ester-codrug contains a biolabile ester linkage that can
be cleaved by hydrolytic enzymes like esterase as soon as it
reaches the epidermal region of the skin to release the parent
compounds (Vaddi, et al. (2009), Prusakiewicz, et al. (2006),

Oesch, et al. (2007). Once in the skin the DIC will act locally
to keep the pores open while NTX is delivered systemically.
The overall objective of this paper is to use a codrug
approach to reduce the inflammatory response in combination with occlusion for delayed barrier recovery following
MN treatment to reach the ultimate goal of a seven day patch
system.
Materials and Methods
Chemicals
Naltrexone HCl was purchased from Mallinckrodt (St.
Louis, Mo.), diclofenac acid from AK Scientific, Inc.
(Mountain view, CA) and diclofenac sodium salt from TCI
America (Portland, Oreg.). Water was purified using
NANOpure Diamond™, Barnstead water filtration system.
Hanks' balanced salts modified powder, propylene glycol
and ethanol, 200 proof were purchased from Sigma (St.
Louis, Mo.). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sodium bicarbonate, sodium acetate,
acetic acid and gentamicin sulfate and were obtained from
Fis her Scientific (Fairlawn, N .J.). 1-0ctanesulfonate,
sodium salt was obtained from Regis Technologies, Inc
(Morton Grove, Ill.). Trifluroacetic acid (TFA), triethylamine (TEA) and acetonitrile (ACN) were obtained from EMD
chemicals (Gibbstown, N.J.). Natrosol® (hydroxyethlycellulose) was obtained from Hercules. Chemicals for codrug
synthesis were purchased from Alfa Aessar.
Synthetic Procedure for Codrug
Diclofenac sodium salt was dissolved in 1:1 (Ethyl
acetate:Water) mixture and acidified with concentrated
hydrochloric acid. Organic layer was separated and aqueous
layer treated with ethyl acetate two times. Combined organic
layer was dried on anhydrous sodium sulfate and rotary
evaporated to remove reaction solvents. Diclofenac free acid
was activated with DCC (N, N'-Dicyclohexyl carbodiimide)) and DMAP (4-Dimethylaminopyridine) in anhydrous
tetrahydrofuran. After two hours, equivalent naltrexone was
added in dry tetrahydrofuran. Combined reactants were
allowed to stir over night under nitrogen atmosphere. After
completion of the reaction, solvents were removed under
reduced pressure and reaction crude mixture purified by
flash silica gel column chromatography eluting with 80%
ethyl acetate and 20% cyclohexane and codrug-1 was
obtained in 56% (Scheme-I) yield. The codrug-1 was dissolved in I, 4-dioxane and an equimolar amount of 2M
hydrochloric acid in dioxane was added and refluxed for 1.5
hrs, and precipitated with hexanes to get hydrochloride salt
of codrug-24 (Scheme-I)
1
HNMR (CDC1 3 , 300 MHz): o 7.29 (m, 2H), 7.19 (t, lH),
6.93 (m, 2H), 6.75 (d, lH), 6.60 (d, 2H), 6.57 (d, lH), 4.78
(s, lH), 3.67 (s, 2H), 3.12 (m, 2H), 2.79 (m, lH), 2.32 (t,
2H), 2.27 (m, 2H), 2.05 (m, 2H), 1.69 (m, 2H), 1.62, (m,
2H), 0.46 (m, lH), 0.31 (m, 2H), 0.30 (m, 2H)
13
CNMR(CDC1 3 , (300 MHz): o 4.22, 4.41, 9.77, 23.31,
31.09, 31.59, 36.45, 38.50, 43.75, 51.01, 59.48, 62.15,
70.28, 90.93, 118.75, 119.52, 122.45, 123.05, 124.19,
124.31, 128.30, 128.97, 129.73, 130.38, 130.64, 131.31,
132.63, 138.09, 142.92, 147.77, 169.98, 207.67
HRMS: Calculated for C 34H320 5 N 2 Cl 2 618.1688 and
found 618.1697.
Hydrochloride Salt of Codrug-24
1
HNMR (CDC1 3 , 300 MHz): 09.98 (bs, NW) 7.33 (m,
2H), 7.13 (t, 111), 6.99 (m, 3H), 6.61 (d, lH), 6.57 (d, lH),
4.97 (s, lH), 4.73 (s, lH), 4.10 (s, 2H), 3.60 (m, 2H), 3.14
(m, 4H), 2.92 (m, lH), 2.65 (m, 2H), 2.41 (d, lH), 1.82 (m,
3H), 1.25 (m 2H), 0.84 (m, 4H), 0.62 (m, lH)
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Quantitative Analysis
NTX, DIC and the codrug concentrations in all samples
were quantified using a HPLC assay which is a modified
version of the previously reported NTX assay (Milewski and
Stinchcomb (2011)). The HPLC system consisted of a
Waters 717 plus auto sampler, a Waters 600 quaternary
pump, and a Waters 2487 dual wavelength absorbance
detector with Waters Empower™ software. A Perkin Elmer
Spheri5 VL Cl8 column (5µ, 220x4.6 mm), a Cl8 guard
column (15x3.2 mm) was used with the UV detector set at
a wavelength of 280 nm. The mobile phase consisted of
70:30 (v/v) ACN:(0.1% TFA with 0.065% I-octane sulfonic
acid sodium salt, adjusted to pH 3.0 with TEA aqueous
phase). Samples were run at a flow rate of 1.5 ml/min with
a run time of 8.5 min. The injection volume used was 25 µl
for receiver samples and I 00 µl for the skin samples. For the
plasma samples the mobile phase consisted of 50:50 (v/v)
ACN:(O.I % TFA with 0.065% I-octane sulfonic acid
sodium salt, adjusted to pH 3.0 with TEA aqueous phase).
Samples were run at a flow rate of 1.0 ml/min with a run
time of 37 minutes and injection volume of 25 µ!.
Chemical and Enzymatic Stability
Chemical and enzymatic stability was determined for the
codrugs. For chemical stability studies, the codrug was put
in prewarmed 0.3M acetate buffer pH 5.0 after solubilization
in <5% ACN, if required, at 32° C. in an incubator. Samples
were withdrawn at regular intervals and injected into the
HPLC after appropriate dilutions. Enzymatic stability studies are important for estimation of conversion of codrugs in
the plasma. For plasma stability studies prewarmed HGP
plasma at 37° C. was spiked with codrug solution and
samples were withdrawn at regular intervals. 100 µl of
plasma sample was extracted with I ml of I: I ACN:ethyl
acetate, vortexed, centrifuged at I 0,000 rpm for 20 minutes
on a bench top Eppendorf Mini Spin®. The supernatant was
decanted into a glass tube and evaporated under nitrogen.
Samples were reconstituted in I 00 µl ACN and injected onto
the HPLC. All stability data was analyzed using pseudo first
order kinetics. All stability studies were carried out at least,
in triplicate.
In Vitro Diffusion Studies
The in vitro permeation experiments were carried out to
determine the transdermal flux of the parent drugs and the
codrug, permeation coefficients as well as the concentration
of the drug molecules in the skin at the end of the study. For
all in vitro experiments Yucatan miniature pig (YP) skin was
used. Full thickness skin was obtained by removing the
subcutaneous fatty tissue by scalpel dissection, and stored at
-20° C. A PermeGear flow-through (In-Line, Riegelsville,
Pa., USA) diffusion cell system was used for the skin
permeation studies. Skin for MN treatment was placed on a
wafer of polydimethylsiloxane polymer, which mimics the
underlying mechanical support of tissue because of its
comparable structural flexibility and elasticity. The skin was
pierced 20 times with a 5 MN array (making 100 individual
and non-over lapping piercings) before mounting the skin in
the diffusion cell. MN pores were distributed evenly within
the 0.95 cm2 area of skin. Untreated skin samples were
mounted directly onto the diffusion cells. The setup was
maintained at 32° C. using a circulating water bath. Data
collected using a minimum of 3-4 cells per treatment group.
The receiver solution was water alkalified to pH 7.4 containing 20% ethanol at 37° C. Gentamycin sulfate (50 mg/L)
was added to the receiver for 7 day studies as an antibacterial
agent. The receiver flow rate was adjusted to 1.5 ml/h to
maintain skin conditions. Each cell was charged with 0.25
ml of the donor and the diffusion cells were covered with a

stopper to prevent evaporation of formulation. Samples were
collected at regular increments over 48 hours or for the
length of the treatment. Drug was concentrated I 0 fold by
evaporating I ml of the collected sample under nitrogen and
reconstituting in I 00 µl of ACN for quantification. All
samples were stored at 4 ° C. until analyzed by HPLC. The
skin was removed at the end of the study and the treatment
area was diced into small pieces using a scalpel after
removing all excess drugs from top of the skin. Drug was
extracted out by immersing the skin pieces in ACN overnight in a shaker water bath at 32° C. Samples were injected
into the HPLC after appropriate dilution for quantitative
analysis. The donor was also removed and quantified at the
end of the study by direct injection onto HPLC after suitable
dilution using ACN. All data was analyzed using Fick's first
law of diffusion. Jss =P* li.C where Jss is the steady state flux,
P is the permeability coefficient and li.C is the concentration
difference between the donor and the receiver. Since the
receiver is maintained at sink conditions li.C is essentially
the concentration of the donor. Steady state flux is obtained
from a plot of cumulative amounts permeated per time.
Permeability coefficients can be calculated using the known
donor concentration.
In Vivo Studies
Fabrication of Transdermal Patches
The transdermal patches were fabricated by sandwiching
a blend of nitrile rubber and polyvinyl chloride plastic ring
barrier to create a reservoir between the skin and the
impermeable backing membrane (Scotchpak™ #1109
SPAK 1.34 MIL Heat Sealable Polyester Film) and an
ARcare® 7396 adhesive around the edge of the rubber
spacer. 3MTM double sided tape was used on either side of
the rubber to attach the backing on one side and to maintain
contact with the skin on the other side and prevent evaporation of the formulation.
Dose Preparation and Application
All animal experiments were approved by the University
of Kentucky IACUC. A proof of concept in vivo experiment
was carried out. 4% w/w gels were prepared with the
hydrochloride salt form of the codrug. Gels were formulated
by dissolving 4% codrug salt in PG: buffer at pH 5.0=10:90
and 3.0% hydroxyethylcellulose (HEC) polymer (required
to have a gel formulation). Polymer was dissolved over a 30
minute period to obtain a homogenous gel. The solution was
stirred until a viscous gel resulted and then left at room
temperature for I 1h to 2 hours to remove bubbles and ensure
complete polymerization. The gel was saturated with excess
solid and therefore was cloudy. MN treated animals were
first cleaned topically with isopropyl alcohol, and 50 MN
array was applied twice mutually perpendicular to each
other to give a total of 100 pores at each site. 0.3 mL gel
doses were applied to the dorsal region of the HGP. After
application of the gel the skin was occluded with the
occlusive patch and biocclusive tape was applied to prevent
evaporation of the formulation. The patch was changed with
new formulation at 3.5 days such that more than 50% intact
codrug was always present in formulation. A control experiment was also carried out to look at the effect of NTX HCl
alone in the same vehicle on pore closure kinetics. A 9%
solution ofNTX HCl was used to prepare a 3% HEC gel and
all other methods of application were constant with the
codrug gel. The patches were removed to obtain data at
successive 24 h time intervals.
Staining
The patches were removed at predetermined time points
and the site was cleaned with sterile gauze. Gentian violet/
India ink was applied as the dyeing agent at the MN treated
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sites and allowed to dry before excess dye was removed with
ethanol and gauze. Both the dyes stain the viable epidermis
but not the intact SC. Hence, a grid is observed only in the
presence of micropores in the skin, no staining is observed
in its absence.
Statistical Analysis
Data for all experiments are reported as mean±standard
deviation. Statistical analysis of data will be carried out with
Students' t-test and one way ANOVA with post hoc Tukey's
pairwise tests, ifrequired, using SIGMA-STAT (SPSS, Inc.,
Chicago, Ill., USA) software. P<0.05 will be considered to
be statistically significant.
Results and Discussion
Synthesis. The codrug and it's hydrochloride salt were
synthesized successfully. The structures were verified.
HPLC method development. HPLC assay development
for the parent drugs and the codrug was the first step towards
quantification of the data. The retention time of NTX was
2.3 minutes, DIC was 3.5 minutes and codrug was 6.5
minutes. The retention time for the same compounds in
plasma samples were 3.3 minutes, 16 minutes and 33
minutes. All retention times reported are value±0.1 minutes.
Samples were analyzed within a linear range of standard
curve for all the three compounds from 100-10000 ng/ml.
The standard solutions exhibited excellent linearity over the
entire concentration range employed in the assays.
Stability studies. The chemical and enzymatic stability
data indicated that the chemical half-life of the codrug in the
pH 5.0 buffer was 3.9±0.56 days and the enzymatic half-life
in the HGP plasma was 6.4±0.84 minutes. In both the studies
regeneration of the parents were observed with the degradation of the codrug. The chemical stability indicates that
the codrug is not stable enough in an aqueous formulation
for the development of a 7-day transdermal drug delivery
system. But still it could be utilized as a learning tool for
understanding the bioconversion of the codrug in the epidermal region of the skin as well as for proof of concept that
the codrug methodology could work to enhance the drug
delivery window following one time application of the MN.
The plasma stability study indicates that even if intact
codrug permeates the skin and reaches the systemic circulation it would cleave back to the parent drugs almost
immediately thus contributing to the naltrexone flux. The
systemic concentration of diclofenac should not be of concern since it would be orders of magnitude lower compared
to therapeutically relevant systemic doses.
In vitro experiments. The goal of the first set of in vitro
experiments was to estimate flux and skin concentration of
the base form of the codrug. A saturated donor solution was
used consisting of propylene glycol (PG):ethanol: water=43:
43:14 and had a concentration of 4.5 mg/ml. 4 treatment
groups each having 3 diffusion cells (MN treatment) were
dosed and then cells were removed every 12 hours to obtain
the skin concentration of the parent drugs as well as the
codrug at different timepoints. An intact skin control was
also present for the entire length of the study (48 hours).
Steady state flux was obtained both from NTX and DIC of
0.42±0.12 nmol/(cm2 /h) and 0.1910.06 nmol/(cm2 /h)
respectively (FIG. 14A). The flux ofNTX was significantly
higher compared to the flux of DIC (p<0.05). The skin
concentration data shows that the codrug degraded in the
skin to regenerate back the parent drugs even at 24 hours and
amount of parent drugs from the codrug increased with time.
It also showed that the DIC increased in the skin with time
and was higher compared to the NTX at 48 hours.
The codrug cleaved, and NTX flux was obtained from the
base form of the codrug, although it was not high enough to

produce therapeutic efficacy. As also noted from the flux and
skin concentration data, significantly higher amounts of
naltrexone was found in the receiver while diclofenac was
retained in the skin in higher concentration at 48 h. This
difference in flux and skin concentration could be attributed
to the difference in physicochemical properties of the drug
molecules. While naltrexone is positively charged at the skin
surface pH of 5 (ref), at least 90% of the diclofenac will be
negatively charged. Since skin is known to possess a negative charge due to presence of negatively charged carboxylic
acid groups this might lead to slower migration and higher
retention of diclofenac molecules in the skin. Since the
hypothesis behind the project is based on the fact that
diclofenac would work locally to reduce subclinical inflammatory response thus enhancing the drug delivery window,
this characteristic of the molecules would be beneficial in
the long term.
From literature it is known that a charged species has
higher flux through MN treated skin compared to a nontreated control. This property is attributed to the enhanced
solubility of a charged species in an aqueous donor rather
than the molecular species itself (Banks, et al. (2008).
Viscosity of the donor formulation also has a predominant
effect on the flux across MN treated skin where it has been
shown that 17 fold flux enhancement was obtained using a
low viscosity, aqueous donor compared to a high viscosity
propylene glycol (PG) rich donor (concentration was maintained at 110 mg/ml). No significant difference in flux was
observed across untreated intact skin using the above
donors. Hence the hydrochloride salt form of the codrug was
tested for higher solubility and flux in aqueous donor for
subsequent experiments.
In the next set of experiment hydrochloride salt of codrug
(FIG. 12) was used as the donor solution with a concentration of39.3 mg/ml in 0.3M acetate buffer at pH 5.0. The flux
of NTX from the codrug salt was 5.42±1.5 nmol/(cm2 /h)
(FIG. 16) and the skin concentration for both NTX and the
codrug increased (data not shown). Therefore a 13 fold flux
enhancement was obtained by using the salt form over the
free base form (p<0.005) which can be attributed to the
solubility enhancement of the salt form in an aqueous donor.
Precipitation issues were observed with purely aqueous
donor, so in vitro formulation development experiment was
carried out by varying the amount of PG in the donor. 10%,
25% and 50% PG was used with the salt form and it was
observed that while there was no significant difference in
flux between the aqueous formulation and 10% PG containing formulation (p<0.05), but flux decreased significantly
for higher concentrations of PG. All experiments were
carried out with saturated donor solution. The data was
compared using one way ANOVA and Tukey's posthoc
analysis for pair wise multiple comparisons. The 10% PG
containing formulation was hence chosen for in vivo studies.
In vivo studies. The pores can be clearly visualized with
gentian violet in FIG. 17 (A) immediately following MN
treatment. In panel (B) the pores cannot be visualized at day
4 (96 h) pores treatment with MN followed by application of
NTX HCl gel under occlusion. This is in agreement with
previously reported data in pharmacokinetic studies where it
has been shown that the micropores close anywhere between
a 48-72 h timeline following MN treatment under occlusion
(Stan PNAS ref). Pores can be visualized by India iuk
staining in panel C where the hydrochloride salt form of the
codrug was used following MN treatment indicating that the
pores can stay open up to a 7 day time point. Therefore, it
can be concluded from the studies that the codrug is effective
in keeping the pores open analogous to our hypothesis.
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From the studies so far it can be concluded that the codrug
cleaved back to parent drugs both in stability studies as well
as in vitro studies. The salt form of the codrug improved
solubility and flux significantly in in vitro studies. Subsequent in vivo studies with the salt form in an optimized 10%
PG containing formulation kept the pores open for a 7 day
target drug delivery window but the flux of NTX from the
codrug was not high enough to quantify in an hairless guinea
pig model. This could be predicted from clearance estimation from previous pharmacokinetic studies with NTX in the
same animal model based on size of treated area since
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Jss* A~Css*Cl

In this case with 4 patches A is 400 MN treatments, flux
is 5.5 nmol/cm2 /h and Cl is 5.6 L/h which leads to a Css of
around 1 ng/ml, the LLOQ on the LCMS assay. Hence
reliable pharmacokinetic data could not be obtained from
this codrug. Hence, physicochemical optimization is
required to obtain a molecule that would have higher stability and permeability in a range that can be clinically
applicable, thus making the codrug approach applicable for
pore lifetime enhancement and NTX delivery.
Codrugs will possess a variety of different linking groups
of diverse susceptibility to hydrolysis including carboxylate
ester, carbamate ester and carbonate ester. A nontoxic linker
moiety will be used in between, ifrequired (e.g. polyethylene glycol, alkyl chain). It has been shown that the ionized
form of the drug has a much higher flux compared to the
unionized form via the MN pathway. This phenomenon is
mainly due to enhanced solubility of the ionized species in
formulation (Banks, et al. (2008).
The main rate limiting step of the codrug approach is the
synthesis of the complex codrugs as well as the stability in
formulation. Solubility issues in an aqueous medium might
also be rate limiting since most of the codrugs have a very
high predicted log P value.
The theoretical flux values required for NTX in vitro to
achieve therapeutically relevant concentrations in vivo is
around 12-90 nmol/cm2 /h from a 25 cm2 patch, based on the
oral dosing regimen. On the other hand the flux of DIC
required to have any systemic effect is almost an order of
magnitude higher. Thus, DIC related systemic toxicity
should not be an issue with this design.
In an aqueous environment codrugs should have a lower
chemical stability, since it undergoes hydrolysis in formulation, but higher solubility leading to higher flux via a
microchannel pathway (Banks, et al. (2008). Hence a hydrochloride salt form was used to enhance solubility and
permeation. The viscosity of the donor solution has also
been shown to have an effect on MN enhanced delivery
(Milewski and Stinchcomb (2011) ). So optimization based
on formulation viscosity was carried out by adding different
concentrations of propylene glycol (PG) to the codrug salt in
an aqueous vehicle.
Throughout this document, various references are mentioned. All such references are incorporated herein by reference to the same extent as if each individual reference was
specifically and individually indicated to be incorporated by
reference, including the references set forth in the following
list:
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What is claimed is:
1. A compound having a first moiety derived from an
opioid; and
a second moiety derived from a cyclooxygenase (COX)
enzyme inhibitor;
wherein said first moiety is liuked to said second moiety
to form a single chemical entity;
wherein the compound has a structure selected from the
group consisting of:
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2. The compound of claim 1, wherein the opioid and the
COX enzyme inhibitor are linked by a linker moiety.
3. The compound of claim 2, wherein the linker moiety is
cleavable.
4. The compound of claim 3, wherein the linker moiety is
cleavable by hydrolysis and/or enzymatic digestion.
5. The compound of claim 2, wherein the linker moiety
confers increased aqueous solubility to the compound.
6. A method for treating a subject, comprising
identifying a subject in need of treatment for a condition
selected from the group consisting of narcotic dependence, alcohol dependence, amphetamine dependence,
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and smoking dependence; and delivering to the subject
a therapeutically effective amount of the compound of
claim 1.
7. The method of claim 6, wherein following delivery to
the subject, the compound is transformed into at least two
active drug molecules.
8. The method of claim 7, wherein the transformation is
by hydrolysis and/or enzymatic digestion.
9. The method of claim 6, wherein the compound is
delivered transdermally.
10. The method of claim 9, wherein compound achieves
improved duration of microporation-assisted delivery of the
opioid as compared to the parent.
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